

Connecting via Winsock to STN

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal645vlf

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files  
NEWS 3 Feb 06 Engineering Information Encompass files have new names  
NEWS 4 Feb 16 TOXLINE no longer being updated  
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure  
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA  
NEWS 7 May 07 DGENE Reload

NEWS EXPRESS May 23 CURRENT WINDOWS VERSION IS V6.0a,  
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:10:44 ON 25 MAY 2001

=> file biosis, caba, caplus, embase, lifesci, medline, scisearch, uspatful, japio  
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.30	0.30

FILE 'BIOSIS' ENTERED AT 11:11:44 ON 25 MAY 2001  
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'CABA' ENTERED AT 11:11:44 ON 25 MAY 2001  
COPYRIGHT (C) 2001 CAB INTERNATIONAL (CABI)

FILE 'CAPLUS' ENTERED AT 11:11:44 ON 25 MAY 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:11:44 ON 25 MAY 2001  
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'LIFESCI' ENTERED AT 11:11:44 ON 25 MAY 2001  
COPYRIGHT (C) 2001 Cambridge Scientific Abstracts (CSA)

FILE 'MEDLINE' ENTERED AT 11:11:44 ON 25 MAY 2001

FILE 'SCISEARCH' ENTERED AT 11:11:44 ON 25 MAY 2001  
COPYRIGHT (C) 2001 Institute for Scientific Information (ISI) (R)

FILE 'USPATFULL' ENTERED AT 11:11:44 ON 25 MAY 2001  
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 11:11:44 ON 25 MAY 2001  
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

=> s Chlamydia

L1 59198 CHLAMYDIA

=> s l1 and composition?

L2 1447 L1 AND COMPOSITION?

=> s l2 and treatment?

L3 925 L2 AND TREATMENT?

=> s l3 and Chlamydia trachomatis

L4 339 L3 AND CHLAMYDIA TRACHOMATIS

=> s l4 and vaccine?

L5 98 L4 AND VACCINE?

=> d l5 bib ab 1-98

L5 ANSWER 1 OF 98 CAPLUS COPYRIGHT 2001 ACS

AN 2000:402007 CAPLUS

DN 133:53686

TI Chlamydial antigens and genomic DNA sequences for **treatment** and  
diagnosis of chlamydial infection

IN Probst, Peter; Bhatia, Ajay; Skeiky, Yasir A. W.; Fling, Steven P.; Jen,  
Shyian; Stromberg, Erica Jean

PA Corixa Corporation, USA

SO PCT Int. Appl., 256 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000034483	A2	20000615	WO 1999-US29012	19991208
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				
	CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,				
	IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				
	MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,				
	SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6166177	A	20001226	US 1998-208277	19981208
PRAI	US 1998-208277	A	19981208		
	US 1999-288594	A	19990408		
	US 1999-410568	A	19991001		
	US 1999-426571	A	19991022		

AB Compds. and methods for the diagnosis and **treatment** of  
Chlamydial infection are disclosed. The compds. provided include  
polypeptides that contain at least one antigenic portion of a  
**Chlamydia** antigen and DNA sequences encoding such polypeptides.  
**Chlamydia** antigens were isolated by expression cloning of a

genomic DNA library of *C. trachomatis* LGV II, and shown to induce T cell proliferation and interferon-.beta. prodn. Immune responses of human PBMC and T cell lines are generated against the **Chlamydia** antigens. Pharmaceutical **compns.** and **vaccines** comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits contg. such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biol. samples.

L5 ANSWER 2 OF 98 CAPLUS COPYRIGHT 2001 ACS

AN 1999:819417 CAPLUS

DN 132:77610

TI Antigenic complex comprising immunostimulatory peptide, CD4, and chemokine receptor domain for HIV **treatment** and immune disorders

IN Wang, Chang Yi

PA United Biomedical Inc., USA

SO PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9967294	A1	19991229	WO 1999-US14030	19990621
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6090388	A	20000718	US 1998-100409	19980620
	AU 9947048	A1	20000110	AU 1999-47048	19990621
	EP 1098910	A1	20010516	EP 1999-930523	19990621
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
PRAI	US 1998-100409	A2	19980620		
	WO 1999-US14030	W	19990621		
AB	The invention provides peptides comprising a sequence homologous to a portion of the CDR-2 like domain of CD4, covalently linked to a helper T cell epitope, and optionally to other immunostimulatory sequences as well. The invention provides for the use of such peptides as immunogens to elicit the prodn. in mammals of high titer polyclonal auto-antibodies, which are specific to CD4 surface complex. These auto-antibodies prevent binding of HIV viral particles to CD4+ cells. The peptides are useful in pharmaceutical <b>compns.</b> , to provide an immunotherapy for HIV infection and to protect against HIV infection.				

RE.CNT 2

RE

(1) United Biomedical Inc; WO 9526365 A1 1995 CAPLUS

(2) Vita, C; Biopolymers 1998, V47, P93 CAPLUS

L5 ANSWER 3 OF 98 CAPLUS COPYRIGHT 2001 ACS

AN 1999:819416 CAPLUS

DN 132:77609

TI Peptide **composition** as immunogen for the **treatment** of allergy

IN Wang, Chang Yi; Walfield, Alan M.

PA United Biomedical Inc., USA

SO PCT Int. Appl., 155 pp.

CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9967293	A1	19991229	WO 1999-US13959	19990621
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9945802	A1	20000110	AU 1999-45802	19990621
	BR 9911389	A	20010320	BR 1999-11389	19990621
	EP 1090039	A1	20010411	EP 1999-928818	19990621
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			

PRAI US 1998-100287 A2 19980620  
WO 1999-US13959 W 19990621

AB The invention provides peptides comprising a sequence homologous to a portion of the third const. domain of the epsilon heavy chain of IgE, covalently linked to either (1) a carrier protein, or (2) a helper T cell epitope, and optionally to other immunostimulatory sequences as well. The invention provides for the use of such peptides as immunogens to elicit the prodn. in mammals of high titer polyclonal antibodies, which are specific to a target effector site on the epsilon heavy chain of IgE. The peptides are expected to be useful in pharmaceutical **compns.**, to provide an immunotherapy for IgE-mediated allergic diseases.

RE.CNT 5

RE

- (1) Burt, D; Eur J Immunol 1987, V17, P437 CAPLUS
- (2) Burt, D; Molecular Immunology 1987, V24(4), P379 CAPLUS
- (3) Genentech Inc; WO 9304173 A1 1993 CAPLUS
- (4) Helm, B; Nature 1988, V331, P180 CAPLUS
- (5) Vercelli, D; Letters to Nature 1989, V338, P649 CAPLUS

L5 ANSWER 4 OF 98 CAPLUS COPYRIGHT 2001 ACS

AN 1999:375673 CAPLUS

DN 131:14867

TI **Chlamydia trachomatis** genomic sequence and polypeptides and their fragments and uses for the diagnosis, prevention and **treatment** of infection

IN Griffais, Remy

PA Genset, Fr.

SO PCT Int. Appl., 292 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9928475	A2	19990610	WO 1998-IB1939	19981127
	WO 9928475	A3	19991118		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

AU 9912545            A1    19990616            AU 1999-12545        19981127  
 EP 1032676            A2    20000906            EP 1998-955832      19981127  
       R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
           IE, FI  
 BR 9814912            A    20001003            BR 1998-14912        19981127  
 PRAI FR 1997-15041        A    19971128  
       FR 1997-16034        A    19971217  
       US 1998-107077        P    19981104  
       WO 1998-IB1939        W    19981127

AB The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of **Chlamydia trachomatis**, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metab., in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The complete genome sequence of C. trachomatis strain LSV2, as well as 1196 open reading frames and the deduced amino acid sequences of their protein products, are claimed in the patent but not provided in the document. The invention also relates to transcriptional gene products of the **Chlamydia trachomatis** genome, such as, for example, antisense and ribozyme mols., which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing **Chlamydia trachomatis** infection. The invention also relates to a method of selecting compds. capable of modulating bacterial infection and a method for the biosynthesis or biodegrdn. of mols. of interest using the said nucleotide sequences or the said polypeptides. The invention finally comprises, pharmaceutical, in particular **vaccine, compns.** for the prevention and/or **treatment** of bacterial, in particular **Chlamydia trachomatis**, infections.

L5 ANSWER 5 OF 98 CAPLUS COPYRIGHT 2001 ACS

AN 1999:244557 CAPLUS

DN 130:277672

TI **Chlamydia** high-molecular-weight protein and its gene sequence and and diagnostic and therapeutic uses

IN Jackson, James W.; Pace, John L.

PA Antex Biologics Inc., USA

SO PCT Int. Appl., 141 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9917741	A1	19990415	WO 1998-US20737	19981001
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9895988	A1	19990427	AU 1998-95988	19981001
	EP 1019028	A1	20000719	EP 1998-949723	19981001
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 9813841	A	20001003	BR 1998-13841	19981001
	ZA 9809012	A	19990412	ZA 1998-9012	19981002
PRAI	US 1997-942596	A	19971002		
	WO 1998-US20737	W	19981001		
AB	A high-mol.-wt. (HMW) protein of <b>Chlamydia</b> , the amino acid				

sequence thereof, and antibodies that specifically bind the HMW protein are disclosed as well as the nucleic acid sequence encoding the same. The gene encoding HMW protein was cloned and sequenced from *C. trachomatis* strains L2, B, and F. The in vitro neutralization model shows that protective antiserum against HMW protein inhibits chlamydial infections of various tissue culture cell lines. **Vaccine compns.**

comprising the HMW protein are effective in a mouse model of salpingitis and fertility. Thus, disclosed are prophylactic and therapeutic **compns.**, comprising the HMW protein, a fragment thereof, or an antibody that specifically binds the HMW protein or a portion thereof, or the nucleotide sequence encoding the HMW protein or a fragment thereof, including **vaccines**.

RE.CNT 4

RE

- (1) Caldwell; US 4427782 A 1984 CAPLUS
- (2) Daniels; US 5725863 A 1998 CAPLUS
- (3) Morrison; US 5071962 A 1991 CAPLUS
- (4) Urnovitz; US 5516638 A 1996 CAPLUS

L5 ANSWER 6 OF 98 CAPLUS COPYRIGHT 2001 ACS

AN 1997:332018 CAPLUS

DN 126:304912

TI **Vaccines** and pharmaceutical **compositions** using membrane vesicles of microorganisms, and methods for preparing them

IN Kadurugamuwa, Jagath L.; Beveridge, Terry J.

PA University of Guelph, Can.

SO Can. Pat. Appl., 116 pp.

CODEN: CPXXEB

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2182637	AA	19970205	CA 1996-2182637	19960802
	WO 9705899	A2	19970220	WO 1996-CA526	19960802
	WO 9705899	A3	19970529		
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM			
	AU 9666095	A1	19970305	AU 1996-66095	19960802
	AU 707131	B2	19990701		
	EP 841944	A2	19980520	EP 1996-925628	19960802
	R:	AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, PT, IE, FI			
	BR 9609882	A	19990727	BR 1996-9882	19960802
PRAI	US 1995-1903		19950804		
	WO 1996-CA526		19960802		

AB The invention relates to novel **vaccines** and pharmaceutical **compns.** using membrane vesicles of microorganisms, methods for prepg. same, and their use in the prevention and **treatment** of infectious diseases. Demonstrated were membrane vesicles (MVs) prepd. and characterized *Pseudomonas aeruginosa*, integration of MVs of *Pseudomonas aeruginosa* or *Shigella flexneri* carrier strain (i.e. *Escherichia coli* or *Salmonella typhi*), predatory role of *Pseudomonas aeruginosa*-derived MVs on other bacteria (*Streptococcus aureus*, *Escherichia coli*) and use as drug delivery system for gentamicin into human intestinal epithelial cell line Henle 407, and construction of *Salmonella typhi* **vaccine** by fusion of *Pseudomonas aeruginosa*- or *Shigella flexneri*-derived MVs with *S. typhi*.

L5 ANSWER 7 OF 98 USPATFULL

AN 2001:74943 USPATFULL  
 TI DNA immunization against chlamydia infection  
 IN Brunham, Robert C., Winnipeg, Canada  
 PA University of Manitoba, Winnipeg, Canada (non-U.S. corporation)  
 PI US 6235290 20010522  
 AI US 1997-893381 19970711 (8)  
 DT Utility  
 EXNAM Primary Examiner: Swartz, Rodney P.  
 LREP Sim & McBurney  
 CLMN Number of Claims: 9  
 ECL Exemplary Claim: 1  
 DRWN 13 Drawing Figure(s); 8 Drawing Page(s)  
 LN.CNT 995  
 AB Nucleic acid, including DNA, immunization to generate a protective immune response in a host, including humans, to a major outer membrane protein of a strain of **Chlamydia**, preferably contains a nucleotide sequence encoding a MOMP or a MOMP fragment that generates antibodies that specifically react with MOMP and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The non-replicating vector may be formulated with a pharmaceutically-acceptable carrier for in vivo administration to the host.

L5 ANSWER 8 OF 98 USPATFULL  
 AN 2001:71101 USPATFULL  
 TI Strategically modified hepatitis B core proteins and their derivatives  
 IN Birkett, Ashley J., Solana Beach, CA, United States  
 PA Immune Complex Corporation, San Diego, CA, United States (U.S. corporation)  
 PI US 6231864 20010515  
 AI US 1999-248588 19990211 (9)  
 PRAI US 1998-74537 19980212 (60)  
 DT Utility  
 EXNAM Primary Examiner: Wortman, Donna C.  
 LREP Welsh & Katz, Ltd.  
 CLMN Number of Claims: 22  
 ECL Exemplary Claim: 1  
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
 LN.CNT 1665  
 AB A strategically modified hepatitis B core protein is described, where an insert is provided, preferably in an immunodominant region of the nucleocapsid protein, containing a chemically reactive amino acid residue. The modified hepatitis B core protein or its aggregated nucleocapsid protein particles can be pendently linked to a hapten to form a modified nucleocapsid conjugate. Such a conjugate is useful in the preparation of **vaccines** or antibodies. The modified hepatitis B core protein can also be modified to include a T cell epitope.

L5 ANSWER 9 OF 98 USPATFULL  
 AN 2001:67798 USPATFULL  
 TI Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides  
 IN Wang, Chang Yi, Cold Spring Harbor, NY, United States  
 PA United Biomedical, Inc., Hauppauge, NY, United States (U.S. corporation)  
 PI US 6228987 20010508  
 AI US 1999-303323 19990430 (9)  
 RLI Division of Ser. No. US 1998-100414, filed on 20 Jun 1998, now patented, Pat. No. US 6025468  
 DT Utility  
 EXNAM Primary Examiner: Fredman, Jeffrey  
 LREP Morgan & Finnegan, LLP  
 CLMN Number of Claims: 13  
 ECL Exemplary Claim: 1

DRWN 3 Drawing Figure(s); 3 Drawing Page(s)

LN.CNT 1264

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel peptide immunogens for eliciting antibodies to LHRH comprising artificial T helper cell epitopes (Th epitopes) designed to provide optimum immunogenicity. The artificial Th epitopes are covalently linked to LHRH and optionally an immunostimulatory sequence.

L5 ANSWER 10 OF 98 USPATFULL

AN 2001:67794 USPATFULL

TI Human respiratory syncytial virus peptides with antifusogenic and antiviral activities

IN Barney, Shawn O'Lin, Cary, NC, United States

Lambert, Dennis Michael, Cary, NC, United States

Petteway, Stephen Robert, Cary, NC, United States

PA Trimeris, Inc., Durham, NC, United States (U.S. corporation)

PI US 6228983 20010508

AI US 1995-485264 19950607 (8)

RLI Division of Ser. No. US 1995-470896, filed on 6 Jun 1995

Continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994

Continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994

Continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933

DT Utility

EXNAM Primary Examiner: Scheiner, Laurie; Assistant Examiner: Parkin, Jeffrey S.

LREP Pennie & Edmonds LLP

CLMN Number of Claims: 62

ECL Exemplary Claim: 1

DRWN 84 Drawing Figure(s); 83 Drawing Page(s)

LN.CNT 32166

AB The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.

L5 ANSWER 11 OF 98 USPATFULL

AN 2001:67175 USPATFULL

TI GidA1

IN Kallender, Howard, King of Prussia, PA, United States

Reichard, Raymond W., Quakertown, PA, United States

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

PI US 6228364 20010508

AI US 1999-360682 19990726 (9)

RLI Division of Ser. No. US 1997-896344, filed on 18 Jul 1997, now patented, Pat. No. US 5994101

DT Utility

EXNAM Primary Examiner: Navarro, Albert

LREP Gimmi, Edward R.; Deibert, Thomas S.; King, William T.

CLMN Number of Claims: 6

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1275

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides gidA1 polypeptides and DNA (RNA) encoding gidA1 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing gidA1 polypeptides to screen for antibacterial compounds.



L5 ANSWER 12 OF 98 USPATFULL  
AN 2001:55947 USPATFULL  
TI Methods and products for stimulating the immune system using  
immunotherapeutic oligonucleotides and cytokines  
IN Krieg, Arthur M., Iowa City, IA, United States  
Weiner, George, Iowa City, IA, United States  
PA University of Iowa Research Foundation, Iowa City, IA, United States  
(U.S. corporation)  
PI US 6218371 20010417  
AI US 1999-286098 19990402 (9)  
PRAI US 1998-80729 19980403 (60)  
DT Utility  
EXNAM Primary Examiner: Yucel, Remy; Assistant Examiner: Zara, Jane  
LREP Wolf, Greenfield & Sacks, P.C.  
CLMN Number of Claims: 23  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Figure(s); 9 Drawing Page(s)  
LN.CNT 2746  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention relates to synergistic combinations of  
immunostimulatory CpG oligonucleotides and immunopotentiating cytokines.  
In particular, the invention relates to methods of stimulating an immune  
response using the synergistic combination of compounds and products  
related thereto.

L5 ANSWER 13 OF 98 USPATFULL  
AN 2001:55723 USPATFULL  
TI Haemophilus adhesin protein  
IN Lingwood, Clifford A., Toronto, Canada  
PA HSC Research & Development Limited Partnership, Toronto, Canada  
(non-U.S. corporation)  
PI US 6218147 20010417  
AI US 1999-456287 19991208 (9)  
RLI Division of Ser. No. US 1996-686528, filed on 26 Jul 1996, now patented,  
Pat. No. US 6054134  
DT Utility  
EXNAM Primary Examiner: Graser, Jennifer  
LREP Burns, Doane, Swecker & Mathis, LLP  
CLMN Number of Claims: 9  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 11 Drawing Page(s)  
LN.CNT 1028  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB An adhesin protein which binds specifically to phosphatidylethanolamine  
(PE), gangliotriaosylceramide (Gg.sub.3) and gangliotetraosylceramide  
(Gg.sub.4) has been isolated and purified from H. influenzae. Also  
provided are immunogenic **compositions** and methods of  
protecting susceptible mammals from diseases caused by bacterial  
pathogens having the adhesin as a surface protein.

L5 ANSWER 14 OF 98 USPATFULL  
AN 2001:51819 USPATFULL  
TI Phenylalanyl tRNA synthetase alpha sub-unit from **Chlamydia**  
**trachomatis**  
IN Brown, James R, Berwyn, PA, United States  
Lawlor, Elizabeth J, Malvern, PA, United States  
Reichard, Raymond W, Quakertown, PA, United States  
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S.  
corporation)  
PI US 6214595 20010410  
AI US 1999-373958 19990813 (9)  
RLI Division of Ser. No. US 1997-899011, filed on 23 Jul 1997, now patented,  
Pat. No. US 5939298  
DT Utility

EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Kerr, Kathleen

LREP Gimmi, Edward R.; Deibert, Thomas S.; King, William T.

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1249

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides phenylalanyl tRNA synthetase (pheS) pheS polypeptides and DNA (RNA) encoding phenylalanyl tRNA synthetase (pheS) pheS polypeptides and methods for producing such polypeptides from **Chlamydia trachomatis** by recombinant techniques. Also provided are methods for utilizing pheS polypeptides to screen for antibacterial compounds.

L5 ANSWER 15 OF 98 USPATFULL

AN 2001:47842 USPATFULL

TI DNA molecules encoding pgp3 protein from **Chlamydia trachomatis**

IN Ratti, Giulio, Siena, Italy

PA Chiron SpA, Italy (non-U.S. corporation)

PI US 6210968 20010403

AI US 1995-465465 19950605 (8)

RLI Division of Ser. No. US 1994-229980, filed on 19 Apr 1994

DT Utility

EXNAM Primary Examiner: Hobbs, Lisa J.

LREP Blackburn, Robert P.; Harbin, Alisa A. Woodcock Washburn Kurtz Mackiewicz & Norris LLP

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 1596

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A new recombinant form of the plasmid-encoded protein pgp3 from **C. trachomatis**, serotype D, was purified by ion exchange column chromatography and shown to be suitable for quantitative immunoassay on clinical samples in an ELISA format.

L5 ANSWER 16 OF 98 USPATFULL

AN 2001:44205 USPATFULL

TI Rata

IN Black, Michael Terence, Chester Springs, PA, United States

Reichard, Raymond W, Quakertown, PA, United States

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

SmithKline Beecham, plc., United Kingdom (non-U.S. corporation)

PI US 6207647 20010327

AI US 1997-896346 19970718 (8)

DT Utility

EXNAM Primary Examiner: Swart, Rodney P.

LREP Gimmi, Edward R.; Diebert, Thomas S.; King, William T.

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1293

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides rata polypeptides and DNA (RNA) encoding rata polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing rata polypeptides to screen for antibacterial compounds.

L5 ANSWER 17 OF 98 USPATFULL

AN 2001:44204 USPATFULL

TI Immunostimulatory nucleic acid molecules

IN Krieg, Arthur M., Iowa City, IA, United States  
Kline, Joel, Iowa City, IA, United States  
Klinman, Dennis, Potomac, MD, United States  
Steinberg, Alfred D., Potomac, MD, United States  
PA University of Iowa Research Foundation, Iowa City, IA, United States  
(U.S. corporation)  
Coley Pharmaceutical Group, Inc., Wellesley, MA, United States (U.S.  
corporation)  
The United States of America as represented by the Department of Health  
and Human Services, Washington, DC, United States (U.S. government)  
PI US 6207646 20010327  
AI US 1996-738652 19961030 (8)  
RLI Continuation of Ser. No. US 1995-386063, filed on 7 Feb 1995  
Continuation-in-part of Ser. No. US 1994-276358, filed on 15 Jul 1994,  
now abandoned  
DT Utility  
EXNAM Primary Examiner: Martinell, James  
LREP Wolf, Greenfield & Sacks, P.C.  
CLMN Number of Claims: 39  
ECL Exemplary Claim: 1  
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)  
LN.CNT 2680

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nucleic acids containing unmethylated CpG dinucleotides and therapeutic  
utilities based on their ability to stimulate an immune response and to  
redirect a Th2 response to a Th1 response in a subject are disclosed.

L5 ANSWER 18 OF 98 USPATFULL

AN 2001:43720 USPATFULL

TI AspS from **Chlamydia trachomatis**

IN Brown, James R., Berwyn, PA, United States

Lawlor, Elizabeth J, Malvern, PA, United States

Reichard, Raymond W, Quakertown, PA, United States

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S.  
corporation)

SmithKline Beecham, plc., United Kingdom (non-U.S. corporation)

PI US 6207162 20010327

AI US 1999-224772 19990104 (9)

RLI Division of Ser. No. US 1997-899244, filed on 23 Jul 1997, now patented,  
Pat. No. US 5882892

DT Utility

EXNAM Primary Examiner: Duffy, Patricia A.

LREP Gimmi, Edward R.; Deibert, Thomas S.; King, William T.

CLMN Number of Claims: 6

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1305

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides aspS polypeptides and DNA (RNA) encoding aspS  
polypeptides and methods for producing such polypeptides by recombinant  
techniques. Also provided are methods for utilizing aspS polypeptides to  
screen for antibacterial compounds.

L5 ANSWER 19 OF 98 USPATFULL

AN 2001:25424 USPATFULL

TI Vectors for the diagnosis and **treatment** of solid tumors  
including melanoma

IN Pawelek, John M., Hamden, CT, United States

Bermudes, David, Wallingford, CT, United States

Low, Kenneth Brooks, Guilford, CT, United States

PA Yale University, New Haven, CT, United States (U.S. corporation)

PI US 6190657 20010220

AI US 1996-658034 19960604 (8)

RLI Continuation-in-part of Ser. No. US 1995-486422, filed on 7 Jun 1995,

now abandoned

DT Utility  
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Sandals, William  
LREP Pennie & Edmonds LLP  
CLMN Number of Claims: 66  
ECL Exemplary Claim: 1  
DRWN 45 Drawing Figure(s); 38 Drawing Page(s)  
LN.CNT 4716

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to the isolation and use of super-infective, tumor-specific vectors that are strains of parasites including, but not limited to bacteria, fungi and protists. In certain embodiments the parasites include, but are not limited to, the bacterium *Salmonella* spp., such as *Salmonella typhimurium*, the bacterium *Mycobacterium avium* and the protozoan *Leishmania amazonensis*. In other embodiments, the present invention is concerned with the isolation of super-infective, tumor-specific, suicide gene-containing strains of parasites for use in **treatment** of solid tumors.

L5 ANSWER 20 OF 98 USPATFULL

AN 2001:22007 USPATFULL

TI HisS from ***Chlamydia trachomatis***

IN Brown, James R, Berwyn, PA, United States  
Lawlor, Elizabeth J, Malvern, PA, United States  
Reichard, Raymond W, Quakertown, PA, United States

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

PI US 6187561 20010213

AI US 1998-210009 19981211 (9)

RLI Division of Ser. No. US 1997-899028, filed on 23 Jul 1997, now patented, Pat. No. US 5858720

DT Utility

EXNAM Primary Examiner: Duffy, Patricia A.  
LREP Gimmi, Edward R.; Deibert, Thomas S.; King, William T.  
CLMN Number of Claims: 9  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1275

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides hisS polynucleotides which encode hisS polypeptide, polynucleotides related thereto, and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing the hisS polynucleotides and polypeptides to screen for antibacterial compounds and for the detection of pathogens.

L5 ANSWER 21 OF 98 USPATFULL

AN 2001:10718 USPATFULL

TI Antigen carbohydrate compounds and their use in immunotherapy

IN McKenzie, Ian F. C., Victoria, Australia  
Apostolopoulos, Vasso, Victoria, Australia  
Pietersz, Geoff Allan, Victoria, Australia

PA Austin Research Institute, Victoria, Australia (non-U.S. corporation)

PI US 6177256 20010123

AI US 1998-223043 19981230 (9)

RLI Continuation of Ser. No. US 1997-833807, filed on 9 Apr 1997, now patented, Pat. No. US 5989552 Continuation of Ser. No. US 1994-340711, filed on 16 Nov 1994, now abandoned

PRAI AU 1993-3223 19931226

DT Utility

EXNAM Primary Examiner: Park, Hankyel  
LREP Dann Dorfman Herrell and Skillman, P.C.  
CLMN Number of Claims: 16  
ECL Exemplary Claim: 1  
DRWN 23 Drawing Figure(s); 10 Drawing Page(s)

LN.CNT 1427

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Conjugates between one or more repeated subunits of an antigen and a carbohydrate polymer are desired. Also described are immunogenic **vaccines** against disease states which contain the conjugates and methods for inducing cell-mediated immune responses. The conjugates may especially contain polymers of the carbohydrate mannose and one or more repeated subunits of human mucin.

L5 ANSWER 22 OF 98 USPATFULL

AN 2001:7881 USPATFULL

TI Lyss

IN Brown, James R, Berwyn, PA, United States

Lawlor, Elizabeth J, Malvern, PA, United States

Reichard, Raymond W, Quakertown, PA, United States

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

PI US 6174714 20010116

AI US 1999-270917 19990316 (9)

RLI Division of Ser. No. US 1997-898780, filed on 23 Jul 1997, now patented, Pat. No. US 5935816

DT Utility

EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Kerr, Kathleen

LREP Gimmi, Edward R.; Deibert, Thomas S.; King, William T.

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1292

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides lysS polypeptides and DNA (RNA) encoding lysS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing lysS polypeptides to screen for antibacterial compounds.

L5 ANSWER 23 OF 98 USPATFULL

AN 2001:4512 USPATFULL

TI ratB

IN Black, Michael Terence, Chester Springs, PA, United States

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

PI US 6171838 20010109

AI US 1997-910313 19970813 (8)

DT Patent

EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Tung, Peter P.

LREP Gimmi, Edward R.; Deibert, Thomas S.; King, William T.

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1361

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides ratB polypeptides and DNA (RNA) encoding ratB polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ratB polypeptides to screen for antibacterial compounds.

L5 ANSWER 24 OF 98 USPATFULL

AN 2000:174803 USPATFULL

TI Compounds and methods for the **treatment** and diagnosis of chlamydial infection

IN Probst, Peter, Seattle, WA, United States

Bhatia, Ajay, Seattle, WA, United States

Skeiky, Yasir A. W., Seattle, WA, United States

PA Corixa Corporation, Seattle, WA, United States (U.S. corporation)  
PI US 6166177 20001226  
AI US 1998-208277 19981208 (9)  
DT Utility  
EXNAM Primary Examiner: Navarro, Albert; Assistant Examiner: Lee, Li  
LREP Seed Intellectual Property Law Group PLLC  
CLMN Number of Claims: 4  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1058

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods for the diagnosis and **treatment** of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydial antigen and DNA sequences encoding such polypeptides. Pharmaceutical **compositions** and **vaccines** comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

L5 ANSWER 25 OF 98 USPATFULL

AN 2000:174122 USPATFULL

TI "Methods and **compositions** for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"

IN Neurath, Alexander Robert, New York, NY, United States

Jiang, Shibo, Jackson Heights, NY, United States

Debnath, Asim Kumar, New York, NY, United States

Strick, Nathan, Oceanside, NY, United States

Dow, Gordon Jay, Santa Rosa, CA, United States

PA New York Blood Center, Inc., New York, NY, United States (U.S. corporation)

PI US 6165493 20001226

AI US 1998-175909 19981020 (9)

RLI Continuation-in-part of Ser. No. US 1998-112130, filed on 8 Jul 1998, now patented, Pat. No. US 5985313

PRAI US 1997-62936 19971022 (60)

US 1998-71017 19980113 (60)

DT Utility

EXNAM Primary Examiner: Azpuru, Carlos A.

LREP Frishauf, Holtz, Goodman, Langer & Chick, P.C.

CLMN Number of Claims: 45

ECL Exemplary Claim: 1

DRWN 8 Drawing Figure(s); 8 Drawing Page(s)

LN.CNT 2097

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for decreasing the frequency of transmission of human immunodeficiency virus or herpesviruses or for preventing the transmission of or treating a sexually transmitted bacterial infection by administering to a human an anti-human immunodeficiency virus amount or an anti-herpesvirus amount or an anti-bacterial amount of cellulose acetate phthalate (CAP) or hydroxypropyl methylcellulose phthalate (HPMCP), such as in micronized form, or a combination thereof, either alone or in combination with a pharmaceutically acceptable carrier or diluent. The CAP and/or HPMCP may be employed as a suspension of micronized particles and may further contain a water miscible, non-solvent for CAP or HPMCP, such as glycerol.

L5 ANSWER 26 OF 98 USPATFULL

AN 2000:160601 USPATFULL

TI Immunological tolerance-inducing agent

IN Holmgren, Jan, Vastra Frolunda, Sweden

Czerkinsky, Cecil, Villefranche sur mer, France

PA Duotol AB, Vastra Frolunda, United States (non-U.S. corporation)

PI US 6153203 20001128  
AI US 1997-883817 19970627 (8)  
RLI Continuation of Ser. No. US 1995-420981, filed on 10 Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-184458, filed on 19 Jan 1994, now patented, Pat. No. US 5681571, issued on 28 Oct 1997 which is a continuation-in-part of Ser. No. US 1993-160106, filed on 30 Nov 1993, now abandoned  
PRAI CH 1993-9303301 19931008  
DT Utility  
EXNAM Primary Examiner: Swartz, Rodney P.  
LREP Darby & Darby  
CLMN Number of Claims: 22  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1142

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An agent comprising a mucosa-binding molecule linked to a specific microbial antigen is disclosed. Further, a method of inducing immunological tolerance in an individual against a specific microbial antigen, including hapten, which causes an unwanted immune response in said individual, comprising administration by a mucosal route of an immunologically effective amount of an immunological tolerance-inducing agent of the invention to said individual, is described.

L5 ANSWER 27 OF 98 USPATFULL

AN 2000:134872 USPATFULL

TI Method for determining susceptibility to Escherichia coli urinary tract infections, method for diagnosing secretors and nonsecretors, and method and medicament for preventing Escherichia coli urinary tract infections

IN Stapleton, Ann, Seattle, WA, United States  
Nudelman, Edward, Seattle, WA, United States  
Hakomori, Sen-itiroh, Seattle, WA, United States  
Stamm, Walter E., Seattle, WA, United States  
Stroud, Mark, Seattle, WA, United States

PA The Regents of the University of Washington, Seattle, WA, United States (U.S. corporation)

The Biomembrane Institute, Seattle, WA, United States (U.S. corporation)

PI US 6130205 20001010

AI US 1995-470045 19950606 (8)

RLI Division of Ser. No. US 1994-352820, filed on 1 Dec 1994, now abandoned which is a division of Ser. No. US 1992-936400, filed on 31 Aug 1992, now patented, Pat. No. US 5374532

DT Utility

EXNAM Primary Examiner: Peslev, Elli

LREP Roylance, Abrams, Berdo & Goodman, L.L.P.

CLMN Number of Claims: 32

ECL Exemplary Claim: 1,2

DRWN 7 Drawing Figure(s); 5 Drawing Page(s)

LN.CNT 1078

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for determining susceptibility to E. coli urinary tract infection comprising assaying a sample of epithelial cells for the presence or absence of at least one of Le.sup.a, sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and an extended globo structure carrying the same terminal epitopes as Le.sup.a, sialosyl galactosyl-globoside or disialosyl galactosyl-globoside or assaying a sample of vaginal secretions for the presence or absence of at least one of sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of Le.sup.a, sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and the extended globo structure, as well as a method for diagnosing secretors and nonsecretors of histo-blood group antigens comprising assaying a sample of vaginal epithelial cells, vaginal secretions or buccal epithelial cells for the presence or

absence of at least one of sialosyl galactosyl-globoside and disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of sialosyl galactosyl-globoside and disialosyl galactosyl-globoside, and a method for diagnosing secretors of histo-blood group antigens comprising assaying a sample of vaginal epithelial cells or vaginal secretions for the presence or absence of at least one of globo H, globo ABO and lacto ABO, and detecting for the presence or absence of the at least one of globo H, globo ABO and lacto ABO and, further, a medicament comprising a biologically effective amount of at least one E. coli bacterial receptor analogue, and a pharmaceutically acceptable diluent, carrier or excipient as well as a method for preventing E. coli urinary tract infection comprising administering to a host a biologically effective amount of at least one E. coli bacterial receptor or bacterial receptor analogue.

L5 ANSWER 28 OF 98 USPATFULL  
AN 2000:114100 USPATFULL  
TI PyrH of Streptococcus pneumoniae  
IN Petit, Chantal Myriam, Wayne, PA, United States  
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)  
PI US 6111074 20000829  
AI US 1998-30978 19980226 (9)  
DT Utility  
EXNAM Primary Examiner: Navarro, Mark; Assistant Examiner: Lee, Li  
LREP Gimmi, Edward R.; King, William T.; Deibert, Thomas S.  
CLMN Number of Claims: 6  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1742

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides pyrH polypeptides and polynucleotides encoding pyrH polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing pyrH polypeptides to screen for antibacterial compounds.

L5 ANSWER 29 OF 98 USPATFULL  
AN 2000:113925 USPATFULL  
TI DNA **vaccines** for eliciting a mucosal immune response  
IN Malone, Robert W., Baltimore, MD, United States  
Malone, Jill G., Baltimore, MD, United States  
PA University of Maryland, Baltimore, Baltimore, MD, United States (U.S. corporation)  
PI US 6110898 20000829  
AI US 1997-862632 19970523 (8)  
PRAI US 1996-18269 19960524 (60)  
DT Utility  
EXNAM Primary Examiner: Brusca, John S.; Assistant Examiner: McGarry, Sean  
LREP Shanks & Herbert  
CLMN Number of Claims: 38  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)  
LN.CNT 1285

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention consists of a method for inducing production of a mucosal immune response in a host by administration of an antigen-encoding polynucleotide preparation, comprising DNA or RNA encoding an antigenic epitope to a mucosal inductor site in the mucosal tissue of the host. Naked DNA may be administered directly to mucosa, for instance in saline drops, or in a recombinant gene expression vector. Preferably, the recombinant gene expression vectors are not capable of replication or dissemination. The invention also includes the use of live viral **vaccines** wherein the viruses include immunostimulatory polynucleotides of the invention. According to a preferred method of the



invention, a target protein antigen is administered through its expression by a recombinant gene expression vector.

L5 ANSWER 30 OF 98 USPATFULL  
AN 2000:109527 USPATFULL  
TI Synthetic peptide **vaccines** for foot-and-mouth disease  
IN Wang, Chang Yi, Cold Spring Harbor, NY, United States  
Shen, Ming, Flushing, NY, United States  
PA United Biomedical, Inc., Hauppauge, NY, United States (U.S. corporation)  
PI US 6107021 20000822  
AI US 1998-100600 19980620 (9)  
DT Utility  
EXNAM Primary Examiner: Salimi, Ali  
LREP Morgan & Finnegan, LLP  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)  
LN.CNT 3425

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the use of a peptide **composition** as an immunogen, with each peptide contained therein comprising a target antigenic site derived from the VP1 capsid protein of Foot-and-Mouth Disease Virus (FMDV). The antigenic site is covalently linked to a helper T cell epitope and, preferably, to other immunostimulatory sequences, preferably by conventional peptide bond(s) through direct synthesis, for the prevention of FMDV infection and eradication of Foot-and-Mouth Disease (FMD). More particularly, the present invention relates to the use of such peptide **composition** as an immunogen to elicit the production in animals including swine, cattle, sheep, goats and susceptible wild species, of high titer polyclonal antibodies that can effectively neutralize, in vitro, multiple strains or serotypes of FMDV, and to the use of such **composition** as a **vaccine** to prevent, and/or reduce the incidence of, FMDV infection regardless of serotype, and thus affect the eradication of FMDV. The present invention also relates to the peptides used in the **compositions**, and to immunoassays and/or diagnostic kits containing one or more of these peptides, and methods of diagnosing FMDV in mammals using such materials.

L5 ANSWER 31 OF 98 USPATFULL  
AN 2000:98204 USPATFULL  
TI **Chlamydia trachomatis** serotype D proteins  
IN Ratti, Givlio, Siena, Italy  
Comanducci, Maurizio, Siena, Italy  
Tecce, Mario F., Siena, Italy  
Giuliani, Marzia M., Siena, Italy  
PA Sclavo SpA, Italy (non-U.S. corporation)  
PI US 6096519 20000801  
AI US 1997-969644 19971113 (8)  
RLI Division of Ser. No. US 1995-467152, filed on 6 Jun 1995, now abandoned which is a division of Ser. No. US 1995-444189, filed on 18 May 1995 which is a continuation of Ser. No. US 1994-180528, filed on 12 Jan 1994, now abandoned which is a division of Ser. No. US 1992-991512, filed on 17 Dec 1992, now abandoned which is a continuation of Ser. No. US 1991-661820, filed on 28 Feb 1991, now abandoned  
PRAI IT 1991-MI314 19910207  
DT Utility  
EXNAM Primary Examiner: Chin, Christopher L.; Assistant Examiner: Swartz, Rodney P.  
LREP Trujillo, Doreen Y.; Harbin, Alisa A.; Blackburn, Robert P.  
CLMN Number of Claims: 2  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Figure(s); 13 Drawing Page(s)  
LN.CNT 1686

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A plasmid isolated from *Clamydia trachomatis* is described, which comprises 8 genes encoding proteins useful in the formulation of **vaccines** or diagnostic test for determining the bacterium or specific antibodies generated during *C. trachomatis* infections; in particular the recombinant fusion MS2-pgp3D protein is described comprising polypeptidic sequences encoded by pCT and immunogenic in the course of infections in man. A method for preparing said protein in *E. coli* further described.

L5 ANSWER 32 OF 98 USPATFULL

AN 2000:91543 USPATFULL

TI Peptide **composition** for prevention and **treatment** of HIV infection and immune disorders

IN Wang, Chang Yi, Cold Spring Harbor, NY, United States

PA United Biomedical Inc., Hauppauge, NY, United States (U.S. corporation)

PI US 6090388 20000718

AI US 1998-100409 19980620 (9)

DT Utility

EXNAM Primary Examiner: Saunders, David; Assistant Examiner: Tung, Mary B.

LREP Morgan & Finnegan LLP

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 3077

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides peptides comprising a sequence homologous to a portion of the CDR-2 like domain of CD4, covalently linked to a helper T cell epitope, and optionally to other immunostimulatory sequences as well. The invention provides for the use of such peptides as immunogens to elicit the production in mammals of high titer polyclonal auto-antibodies, which are specific to CD4 surface complex. These auto-antibodies prevent binding of HIV viral particles to CD4+ cells. The peptides are useful in pharmaceutical **compositions**, to provide an immunotherapy for HIV infection and to protect against HIV infection.

L5 ANSWER 33 OF 98 USPATFULL

AN 2000:80733 USPATFULL

TI Immunostimulating and **vaccine compositions** employing saponin analog adjuvants and uses thereof

IN Marciani, Dante J., Brimingham, AL, United States

PA Galenica Pharmaceuticals, Inc., Frederick, MD, United States (U.S. corporation)

PI US 6080725 20000627

AI US 1999-290606 19990413 (9)

RLI Continuation-in-part of Ser. No. US 1998-81647, filed on 20 May 1998, now patented, Pat. No. US 5977081

PRAI US 1997-47129 19970520 (60)

US 1998-80389 19980402 (60)

DT Utility

EXNAM Primary Examiner: Lee, Howard C.

LREP Sterne, Kessler, Goldstein & Fox, P.L.L.C.

CLMN Number of Claims: 37

ECL Exemplary Claim: 1

DRWN 12 Drawing Figure(s); 11 Drawing Page(s)

LN.CNT 2493

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to **vaccines** comprising (1) one or more bacterial, viral or tumor-associated antigens; and (2) one or more saponin-lipophile conjugate in which a lipophilic moiety such as a lipid, fatty acid, polyethylene glycol or terpene is covalently attached to a non-acylated or desacylated triterpene saponin via a carboxyl group present on the 3-O-glucuronic acid of the triterpene

saponin. The attachment of a lipophile moiety to the 3-O-glucuronic acid of a saponin such as Quillaja desacylsaponin, lucyoside P, or saponin from Gypsophila, Saponaria and Acanthophyllum enhances their adjuvant effects on humoral and cell mediated immunity. Additionally, the attachment of a lipophile moiety to the 3-O-glucuronic acid residue of non- or des-acylsaponin yields a saponin analog that is easier to purify, less toxic, chemically more stable, and possesses equal or better adjuvant properties than the original saponin.

L5 ANSWER 34 OF 98 USPTAFULL  
AN 2000:67442 USPTAFULL  
TI Formulation for use in the prevention of pathogen induced diseases including HIV and HSV  
IN Bergeron, Michel G., Sillery, Canada  
Desormeaux, Andre, Neufchatel, Canada  
Tremblay, Michel, Neufchatel, Canada  
PA Infectio Recherche, Inc., Sainte Foy, Canada (non-U.S. corporation)  
PI US 6068851 20000530  
WO 9742962 19971120  
AI US 1999-51300 19990113 (9)  
WO 1997-CA319 19970509  
19990113 PCT 371 date  
19990113 PCT 102(e) date  
PRAI US 1996-17106 19960509 (60)  
DT Utility  
EXNAM Primary Examiner: Stucker, Jeffrey  
LREP Godfrey & Kahn, S.C.  
CLMN Number of Claims: 42  
ECL Exemplary Claim: 1  
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)  
LN.CNT 763  
AB This invention relates to formulations comprising film-forming components capable of forming per se a physical barrier to pathogens. Thermoreversible gels such as poloxamers are particularly preferred for that use. The film-forming formulations may further comprise microbicides, spermicides or any other drug, which choice is guided by the pathogen, organism or the disease to be inactivated or treated. The formulations are therefore efficient as a physical, and optionally, as a chemical or pharmacological barrier as well as usable as a sustained drug-release system at the locus of administration. A part of the drug may also be entrapped in liposomes or other drug carriers. These formulations are intended for use in the prevention of sexually transmitted diseases, as well as in the **treatment** of infections, cancer, inflammation or any disease or state which requires a pharmacological **treatment**. Formulations are applicable to mucosae, skin and eye, for example.

L5 ANSWER 35 OF 98 USPTAFULL  
AN 2000:61721 USPTAFULL  
TI Recombinant human IGA-J. chain dimer  
IN Capra, J. Donald, Dallas, TX, United States  
Hexham, Jonathan M., Dallas, TX, United States  
Carayannopoulos, Leon N., St Louis, MO, United States  
Max, Edward E., Bethesda, MD, United States  
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)  
The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
PI US 6063905 20000516  
AI US 1997-779597 19970107 (8)  
DT Utility  
EXNAM Primary Examiner: Eyler, Yvonne  
LREP Arnold, White & Durkee  
CLMN Number of Claims: 102

ECL Exemplary Claim: 1  
DRWN 7 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 2003

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are **compositions** and methods of use that comprise engineered IgA antibodies that, when administered to a host are secreted across the epithelium into the mucosal barriers of the body providing external passive immunotherapy against agents such as viral, bacterial and eukaryotic pathogens. Also disclosed are mini antibodies comprising the minimal transcytosis domains.

L5 ANSWER 36 OF 98 USPATFULL

AN 2000:54215 USPATFULL

TI CysS

IN Brown, James R, Berwyn, PA, United States  
Lawlor, Elizabeth J, Malvern, PA, United States  
Reichard, Raymond W, Quakertown, PA, United States

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

PI US 6057432 20000502

AI US 1997-898977 19970723 (8)

DT Utility

EXNAM Primary Examiner: Scheiner, Laurie

LREP Gimmi, Edward R.; Deibert, Thomas S.; King, William T.

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1469

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides cysS polypeptides and DNA (RNA) encoding cysS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing cysS polypeptides to screen for antibacterial compounds.

L5 ANSWER 37 OF 98 USPATFULL

AN 2000:50384 USPATFULL

TI Haemophilus adhesin protein

IN Lingwood, Clifford A., Toronto, Canada

PA HSC Research & Development Limited, Ontario, Canada (non-U.S. corporation)

PI US 6054134 20000425

AI US 1996-686528 19960726 (8)

DT Utility

EXNAM Primary Examiner: Chin, Christopher L.; Assistant Examiner: Graser, Jennifer

LREP Burns, Doane, Swecker & Mathis, LLP

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN 11 Drawing Figure(s); 11 Drawing Page(s)

LN.CNT 1141

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An adhesin protein which binds specifically to phosphatidylethanolamine (PE), gangliosylceramide (Gg.sub.3) and gangliosylceramide (Gg.sub.4) has been isolated and purified from H. influenzae. Also provided are immunogenic **compositions** and methods of protecting susceptible mammals from diseases caused by bacterial pathogens having the adhesin as a surface protein.

L5 ANSWER 38 OF 98 USPATFULL

AN 2000:34416 USPATFULL

TI Human cytomegalovirus DNA sequences

IN Spaete, Richard, Belmont, CA, United States

Cha, Tai-An, San Ramon, CA, United States

PA Aviron, Mountain View, CA, United States (U.S. corporation)

PI US 6040170 20000321  
AI US 1999-253682 19990218 (9)  
RLI Division of Ser. No. US 1997-926922, filed on 10 Sep 1997, now patented,  
Pat. No. US 5925751 which is a division of Ser. No. US 1995-414926,  
filed on 31 Mar 1995, now patented, Pat. No. US 5721354  
DT Utility  
EXNAM Primary Examiner: Park, Hankyel  
LREP Cserr, Luann; Dunn, Tracy  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN 27 Drawing Figure(s); 53 Drawing Page(s)  
LN.CNT 3110

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided are novel Toledo and Towne human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and **compositions** for detecting HCMV infections and in immunogenic **compositions** for preventing HCMV infections.

L5 ANSWER 39 OF 98 USPATFULL

AN 2000:28125 USPATFULL

TI Nucleic acids encoding myocardial peptides

IN Bachmaier, Kurt, Toronto, Canada

Hessel, Andrew John, Toronto, Canada

Neu, Nickolaus, Innsbruck, Austria

Penninger, Josef Martin, Toronto, Canada

PA Amgen Canada Inc., Mississauga, Canada (non-U.S. corporation)

PI US 6034230 20000307

AI US 1999-303862 19990503 (9)

RLI Continuation of Ser. No. US 1998-133774, filed on 12 Aug 1998

DT Utility

EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: De Cloux, Amy

LREP Oleski, Nancy A.; Odre, Steven M.

CLMN Number of Claims: 6

ECL Exemplary Claim: 1,2,3

DRWN No Drawings

LN.CNT 1405

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are novel peptides that modulate inflammatory heart disease. Also disclosed are DNA molecules encoding the peptides, and methods of making the peptides.

L5 ANSWER 40 OF 98 USPATFULL

AN 2000:24473 USPATFULL

TI Immunoassays for detecting chlamydial antigens or antibodies thereto using recombinant or synthetic major outer membrane protein polypeptides as substitute antigens

IN Agabian, Nina, San Francisco, CA, United States

Stephens, Richard, Oakland, CA, United States

Kuo, Cho-Chou, Seattle, WA, United States

Mullenbach, Guy, Oakland, CA, United States

PA Washington Research Foundation, Seattle, WA, United States (U.S. corporation)

PI US 6030799 20000229

AI US 1995-466152 19950606 (8)

RLI Division of Ser. No. US 1993-144095, filed on 28 Oct 1993, now abandoned which is a continuation of Ser. No. US 1991-691639, filed on 25 Apr 1991, now abandoned which is a continuation of Ser. No. US 1986-818523, filed on 13 Jan 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-692001, filed on 14 Jan 1985, now abandoned

DT Utility

EXNAM Primary Examiner: Minnifield, Nita; Assistant Examiner: Baskar, Padma

LREP Townsend and Townsend and Crew

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 8 Drawing Page(s)

LN.CNT 823

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and **compositions** are provided for the production of a polypeptide which is immunologically cross-reactive with a naturally-occurring major outer membrane protein (MOMP) of **Chlamydia trachomatis**. A DNA construct including a replication system recognized by *E. coli*, and an MOMP gene under the transcriptional control of a  $\beta$ -galactosidase promoter and terminator is provided. Recombinant phage  $\lambda$ .gt11/L2/33 was deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, on Jan. 10, 1985 and granted accession no. 40157. L2 B9-F DNA was deposited at the American Type Culture Collection on Dec. 31, 1985, and granted accession No. 40217.

L5 ANSWER 41 OF 98 USPATFULL

AN 2000:18553 USPATFULL

TI Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides

IN Wang, Chang Yi, Cold Spring Harbor, NY, United States

PA United Biomedical, Inc., Hauppauge, NY, United States (U.S. corporation)

PI US 6025468 20000215

AI US 1998-100414 19980620 (9)

DT Utility

EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Pelley, Ronald

LREP Morgan & Finnegan, LLP

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN 3 Drawing Figure(s); 3 Drawing Page(s)

LN.CNT 2155

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel peptide immunogens for eliciting antibodies to LHRH comprising artificial T helper cell epitopes (Th epitopes) designed to provide optimum immunogenicity. The artificial Th epitopes are covalently linked to LHRH and optionally an immunostimulatory sequence.

L5 ANSWER 42 OF 98 USPATFULL

AN 2000:18049 USPATFULL

TI Recombinant avirulent immunogenic *S. typhi* having rpos positive phenotype

IN Curtiss, III, Roy, St. Louis, MO, United States

Nickerson, Cheryl A., Chesterfield, MO, United States

PA Washington University, St. Louis, MO, United States (U.S. corporation)

PI US 6024961 20000215

AI US 1997-970789 19971114 (8)

DT Utility

EXNAM Primary Examiner: Mosher, Mary E.

LREP Howell & Haferkamp, L.C.

CLMN Number of Claims: 41

ECL Exemplary Claim: 1,39

DRWN 10 Drawing Figure(s); 10 Drawing Page(s)

LN.CNT 2837

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Avirulent immunogenic *Salmonella enterica* serotype Typhi and methods therefor are disclosed. The *Salmonella* have an RpoS<sup>sup.</sup> phenotype, an inactivating mutation in one or more genes which renders the microbe avirulent, and a recombinant gene capable of expressing a desired protein. The *Salmonella* are avirulent and have high immunogenicity so that they can be used in **vaccines** and as delivery vehicles for the desired antigen. Also disclosed are methods for preparing the *Salmonella* and **vaccine** delivery vehicles therefor.

L5 ANSWER 43 OF 98 USPATFULL

AN 2000:7077 USPATFULL

TI Method for inducing a systemic immune response to an antigen  
IN See, Jackie R., Reno, NV, United States  
See, Darryl M., Laguna Niguel, CA, United States  
PA Bio-Sphere Technology, Inc., Reno, NV, United States (U.S. corporation)  
PI US 6015576 20000118  
AI US 1997-920374 19970829 (8)  
RLI Continuation of Ser. No. WO 1997-US4634, filed on 24 Mar 1997 which is a  
continuation-in-part of Ser. No. US 1996-621802, filed on 22 Mar 1996,  
now abandoned  
DT Utility  
EXNAM Primary Examiner: Kishore, Gollamudi S.  
LREP Christie, Parker & Hale, LLP  
CLMN Number of Claims: 52  
ECL Exemplary Claim: 1  
DRWN 15 Drawing Figure(s); 9 Drawing Page(s)  
LN.CNT 982

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is provided for inducing a systemic immune response to an  
antigen in a mammal. The method comprises orally administering  
lyophilized multilamellar liposomes containing the antigen. The  
liposomes have a size of from 20 nm to 20 microns. The  
antigen-containing liposomes are absorbed in the Peyer's patches of the  
gut. Sufficient antigen-containing liposomes are taken up by macrophages  
in the Peyer's patches to induce a systemic immune response to the  
antigen.

L5 ANSWER 44 OF 98 USPATFULL

AN 1999:163458 USPATFULL

TI DNA encoding **Chlamydia trachomatis** isoleucyl tRNA  
synthetase polypeptides

IN Brown, James R, Berwyn, PA, United States  
Lawlor, Elizabeth J, Malvern, PA, United States  
Reichard, Raymond W, Quakertown, PA, United States

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S.  
corporation)

PI US 6001602 19991214

AI US 1997-898978 19970723 (8)

DT Utility

EXNAM Primary Examiner: Caputa, Anthony C.; Assistant Examiner: Navarro, Mark

LREP Gimmi, Edward R.; King, William T.; Deibert, Thomas S.

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1675

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides ileS polypeptides and DNA (RNA) encoding ileS  
polypeptides and methods for producing such polypeptides by recombinant  
techniques. Also provided are methods for utilizing ileS polypeptides to  
screen for antibacterial compounds.

L5 ANSWER 45 OF 98 USPATFULL

AN 1999:155485 USPATFULL

TI DNA encoding gidA1 polypeptides

IN Kallender, Howard, King of Prussia, PA, United States  
Reichard, Raymond W, Quakertown, PA, United States

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S.  
corporation)

PI US 5994101 19991130

AI US 1997-896344 19970718 (8)

DT Utility

EXNAM Primary Examiner: Caputa, Anthony C.; Assistant Examiner: Navarro, Mark

LREP Gimmi, Edward R.; King, William T.; Deibert, Thomas S.

CLMN Number of Claims: 28

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1563

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides gidA1 polypeptides and DNA (RNA) encoding gidA1 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing gidA1 polypeptides to screen for antibacterial compounds.

L5 ANSWER 46 OF 98 USPATFULL

AN 1999:150987 USPATFULL

TI HisS polypeptides from *Chlamydia trachomatis*

IN Brown, James R, Berwyn, PA, United States

Lawlor, Elizabeth J, Malvern, PA, United States

Reichard, Raymond W, Quakertown, PA, United States

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

PI US 5989884 19991123

AI US 1998-210124 19981211 (9)

RLI Division of Ser. No. US 1997-899028, filed on 23 Jul 1997, now patented, Pat. No. US 5858720

DT Utility

EXNAM Primary Examiner: Duffy, Patricia A.

LREP Gimmi, Edward R.; King, William T.; Deibert, Thomas S.

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1338

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides hisS polypeptides and DNA (RNA) encoding hisS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing hisS polypeptides to screen for antibacterial compounds.

L5 ANSWER 47 OF 98 USPATFULL

AN 1999:150655 USPATFULL

TI Antigen carbohydrate compounds and their use in immunotherapy

IN McKenzie, Ian F. C., Victoria, Australia

Pietersz, Geoff Allen, Victoria, Australia

Apostolopoulos, Vasso, Victoria, Australia

PA Austin Research Institute, Victoria, Australia (non-U.S. corporation)

PI US 5989552 19991123

AI US 1997-833807 19970409 (8)

RLI Continuation of Ser. No. US 1994-340711, filed on 16 Nov 1994, now abandoned

PRAI AU 1993-3223 19931224

DT Utility

EXNAM Primary Examiner: Knode, Marian C.; Assistant Examiner: Williams, Jay F.

LREP Dann, Dorfman, Herrell And Skillman

CLMN Number of Claims: 7

ECL Exemplary Claim: 1

DRWN 11 Drawing Figure(s); 10 Drawing Page(s)

LN.CNT 1551

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Conjugates between one or more repeated subunits of an antigen and a carbohydrate polymer are desired. Also described are immunogenic **vaccines** against disease states which contain the conjugates and methods for inducing cell-mediated immune responses. The conjugates may especially contain polymers of the carbohydrate mannose and one or more repeated subunits of human mucin.

L5 ANSWER 48 OF 98 USPATFULL

AN 1999:146013 USPATFULL

TI Method for decreasing the frequency of transmission of viral infections using cellulose acetate phthalate or hydroxypropyl methylcellulose



phthalate excipients  
IN Neurath, Alexander Robert, New York, NY, United States  
Debnath, Asim Kumar, Fort Lee, NJ, United States  
Jiang, Shibo, New York, NY, United States  
Strick, Nathan, Oceanside, NY, United States  
Dow, Gordon Jay, Santa Rosa, CA, United States  
PA New York Blood Center, Inc., New York, NY, United States (U.S.  
corporation)  
PI US 5985313 19991116  
AI US 1998-112130 19980708 (9)  
PRAI US 1997-62936 19971022 (60)  
US 1998-71017 19980113 (60)  
DT Utility  
EXNAM Primary Examiner: Azpuru, Carlos  
LREP Frishauf, Holtz, Goodman, Langer & Chick, P.C.  
CLMN Number of Claims: 32  
ECL Exemplary Claim: 1  
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)  
LN.CNT 1403

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for decreasing the frequency of transmission of human immunodeficiency virus or herpesviruses by administering to a human an anti-human immunodeficiency virus amount or an anti-herpesvirus amount of cellulose acetate phthalate (CAP) or hydroxypropyl methylcellulose phthalate (HPMCP), such as in micronized form, or a combination thereof, either alone or in combination with a pharmaceutically acceptable carrier or diluent. The CAP and/or HPMCP may be employed as a suspension of micronized particles and may further contain a water miscible, non-solvent for CAP or HPMCP, such as glycerol.

L5 ANSWER 49 OF 98 USPATFULL

AN 1999:145975 USPATFULL

TI .beta.-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection

IN Neurath, Alexander Robert, New York, NY, United States  
Debnath, Asim Kumar, New York, NY, United States  
Jiang, Shibo, Jackson Heights, NY, United States

PA New York Blood Center, New York, NY, United States (U.S. corporation)

PI US 5985275 19991116

AI US 1995-537245 19950929 (8)

RLI Continuation-in-part of Ser. No. US 1995-492940, filed on 21 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-420573, filed on 12 Apr 1995, now abandoned

DT Utility

EXNAM Primary Examiner: Tsang, Cecillia J.; Assistant Examiner: Delaney, Patrick

LREP Frishauf, Holtz, Goodman, Langer & Chick, P.C.

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 26 Drawing Figure(s); 22 Drawing Page(s)

LN.CNT 2532

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A **composition** is provided which comprises a protein or peptide containing lysines, wherein at least one of the lysines and/or the N-terminal amino group of the protein or peptide, such as casein, .beta.-lactoglobulin, powdered milk or whey, is modified by contact with an aromatic acid anhydride compound, such as trimellitic anhydride, trimellitic anhydride chloride or 3-hydroxyphthalic anhydride. Additionally a **composition** is provided wherein a protein or peptide containing arginines is modified by an arginine modifying agent containing at least one carboxyl group, such as p-carboxyphenylglyoxal. The **compositions** are capable of binding to CD4 cell receptors, such as the HIV-1 or HIV-2 binding site on CD4 cell receptors. The **compositions** are thus useful for the prevention of HIV-1 or

HIV-2 infection, especially by local administration.

L5 ANSWER 50 OF 98 USPATFULL  
AN 1999:121567 USPATFULL  
TI Deformylase  
IN Lonetto, Michael Arthur, Collegeville, PA, United States  
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)  
PI US 5962666 19991005  
AI US 1997-932142 19970916 (8)  
DT Utility  
EXNAM Primary Examiner: Minnifield, Nita  
LREP Gimmi, Edward R.; King, William T.; Deibert, Thomas S.  
CLMN Number of Claims: 22  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1359  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention provides def polypeptides and DNA (RNA) encoding def polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing def polypeptides to screen for antibacterial compounds.

L5 ANSWER 51 OF 98 USPATFULL  
AN 1999:121537 USPATFULL  
TI Peptides capable of modulating inflammatory heart disease  
IN Bachmaier, Kurt, Toronto, Canada  
Hessel, Andrew John, Toronto, Canada  
Neu, Nickolaus, Innsbruck, Austria  
Penninger, Josef Martin, Toronto, Canada  
PA Amgen Canada Inc., Mississauga, Canada (non-U.S. corporation)  
PI US 5962636 19991005  
AI US 1998-133774 19980812 (9)  
DT Utility  
EXNAM Primary Examiner: Eisenschenk, Frank C.; Assistant Examiner: Pelley, Ronald P  
LREP Oleski, Nancy A.; Levy, Ron K.; Odre, Steven M.  
CLMN Number of Claims: 7  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1397  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Disclosed are novel peptides that modulate inflammatory heart disease. Also disclosed are DNA molecules encoding the peptides, and methods of making the peptides.

L5 ANSWER 52 OF 98 USPATFULL  
AN 1999:120887 USPATFULL  
TI Stable pura vectors and uses therefor  
IN Brey, Robert N., Rochester, NY, United States  
Fulginiti, James P., Canandaigua, NY, United States  
Anilionis, Algis, Pittsford, NY, United States  
PA Praxis Biologics, Inc., West Henrietta, NJ, United States (U.S. corporation)  
PI US 5961983 19991005  
AI US 1995-448907 19950524 (8)  
RLI Division of Ser. No. US 1995-380297, filed on 30 Jan 1995 which is a continuation of Ser. No. US 1994-204903, filed on 2 Mar 1994, now abandoned which is a continuation of Ser. No. US 1991-695706, filed on 3 May 1991, now abandoned  
DT Utility  
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.  
LREP Hamilton, Brook, Smith & Reynolds, P.C.  
CLMN Number of Claims: 32

ECL Exemplary Claim: 1  
DRWN 13 Drawing Figure(s); 9 Drawing Page(s)  
LN.CNT 1389

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to a complementation system for the selection and maintenance of expressed genes in bacterial hosts. The invention provides stable vectors which can be selected and maintained by complementation of chromosomal deletion mutations of purA (adenylosuccinate synthetase), obviating the use of antibiotic resistance genes. This system is useful in production organisms during fermentation and in live **vaccine** bacteria, such as attenuated Salmonella typhi. This system allows for selection of chromosomal integrants and for selection and stable plasmid maintenance in the vaccinated host without application of external selection pressure.

L5 ANSWER 53 OF 98 USPATFULL

AN 1999:113367 USPATFULL

TI Dual carrier immunogenic construct

IN Mond, James J., Potomac, MD, United States

Lees, Andrew, Baltimore, MD, United States

PA Henry Jackson Foundation for the Advancement of Military Medicine,  
Rockville, MD, United States (U.S. corporation)

PI US 5955079 19990921

AI US 1995-468359 19950606 (8)

RLI Continuation of Ser. No. US 1995-402565, filed on 13 Mar 1995, now patented, Pat. No. US 5585100 which is a continuation of Ser. No. US 1993-126017, filed on 24 Sep 1993, now abandoned which is a continuation of Ser. No. US 1992-834067, filed on 11 Feb 1992, now abandoned

DT Utility

EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Shaver, Jennifer

LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.

CLMN Number of Claims: 74

ECL Exemplary Claim: 1

DRWN 14 Drawing Figure(s); 14 Drawing Page(s)

LN.CNT 1324

AB A dual carrier immunogenic construct comprised of at least one primary carrier comprising large molecular weight molecule of greater than a 70 KD molecular weight and at least one secondary carrier comprising a T-dependent antigen conjugated to a primary carrier. The dual carrier immunogenic construct may further comprise moieties such as haptens and antigens. Such immunogenic constructs are suitable for use in the diagnosis, **treatment**, and prevention of diseases.

L5 ANSWER 54 OF 98 USPATFULL

AN 1999:109999 USPATFULL

TI Methods for preventing the transmission of or treating patients infected with herpesvirus

IN Neurath, Alexander Robert, New York, NY, United States

Debnath, Asim Kumar, New York, NY, United States

Jiang, Shibo, Jackson Heights, NY, United States

PA New York Blood Center, New York, NY, United States (U.S. corporation)

PI US 5952009 19990914

AI US 1996-703925 19960828 (8)

RLI Continuation-in-part of Ser. No. US 1996-618830, filed on 20 Mar 1996, now abandoned

DT Utility

EXNAM Primary Examiner: Robinson, Douglas W.; Assistant Examiner: Delaney, Patrick R.

LREP Frishauf, Holtz, Goodman, Langer & Chick, P.C.

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 1382

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of preventing the transmission of or treating herpesvirus, such as herpes simplex virus infection, or **Chlamydia trachomatis** comprising administering to a patient a **composition** which comprises: (i) a protein or peptide containing lysines and an N-terminal amino group, wherein at least one of the lysines or the N-terminal amino group of the protein or peptide, such as casein, .beta.-lactoglobulin, powdered milk or whey, is modified by contact with an aromatic acid anhydride compound, such as trimellitic anhydride, trimellitic anhydride chloride or 3-hydroxyphthalic anhydride and/or (ii) a protein or peptide containing arginines, which is modified by an arginine modifying agent containing at least one carboxyl group, such as p-carboxyphenylglyoxal.

L5 ANSWER 55 OF 98 USPATFULL

AN 1999:102667 USPATFULL

TI Method and system for enhanced production of commercially important exoproteins in gram-positive bacteria

IN Kontinen, Vesa, Helsinki, Finland

Sarvas, Matti, Helsinki, Finland

PA The Finnish National Public Health Institute, Helsinki, Finland  
(non-U.S. corporation)

PI US 5945278 19990831

AI US 1998-108920 19980701 (9)

RLI Division of Ser. No. US 1996-507391, filed on 8 Jul 1996, now patented, Pat. No. US 5780261, issued on 14 Jul 1998 which is a continuation-in-part of Ser. No. US 24154

DT Utility

EXNAM Primary Examiner: Guzo, David

LREP Meyer, Esq., Virginia H.

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1173

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a method and expression system for enhancing secretion of hyperproduced homologous and heterologous exoproteins in gram-positive bacteria such as *Bacillus* sp. The method and system comprise overproduction of PrsA protein in a gram-positive bacterial host also overproducing at least one exoprotein of interest. Use of the method and system of the invention results in greatly enhanced secretion of the synthesized exoproteins into the growth medium. Once in the growth medium these secreted exoproteins can be recovered and purified in a straightforward manner.

L5 ANSWER 56 OF 98 USPATFULL

AN 1999:96249 USPATFULL

TI DNA encoding phenylalanyl tRNA synthetase alpha sub-unit from *chlamydia trachomatis*

IN Brown, James R, Berwyn, PA, United States

Lawlor, Elizabeth J, Malvern, PA, United States

Reichard, Raymond W, Quakertown, PA, United States

PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

PI US 5939298 19990817

AI US 1997-899011 19970723 (8)

DT Utility

EXNAM Primary Examiner: Hobbs, Lisa

LREP King, William T.; Gimmi, Edward R.; Jackson, Arthur E.

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1343

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides pheS polypeptides and DNA (RNA) encoding pheS

polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing pheS polypeptides to screen for antibacterial compounds.

L5 ANSWER 57 OF 98 USPATFULL  
AN 1999:92533 USPATFULL  
TI **Chlamydia trachomatis** lysS polynucleotides  
IN Brown, James R., Berwyn, PA, United States  
Lawlor, Elizabeth J, Malvern, PA, United States  
Reichard, Raymond W, Quakertown, PA, United States  
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)  
PI US 5935816 19990810  
AI US 1997-898780 19970723 (8)  
DT Utility  
EXNAM Primary Examiner: Campell, Bruce R.; Assistant Examiner: Priebe, Scott D.  
LREP King, William T.; Gimmi, Edward R.; Jackson, Arthur E.  
CLMN Number of Claims: 36  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1491

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides lysS polypeptides and DNA (RNA) encoding lysS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing lysS polypeptides to screen for antibacterial compounds.

L5 ANSWER 58 OF 98 USPATFULL  
AN 1999:81942 USPATFULL  
TI Human cytomegalovirus DNA sequences  
IN Spaete, Richard, Belmont, CA, United States  
Cha, Tai-An, San Ramon, CA, United States  
PA Aviron, Mountain View, CA, United States (U.S. corporation)  
PI US 5925751 19990720  
AI US 1997-926922 19970910 (8)  
RLI Division of Ser. No. US 1995-414926, filed on 31 Mar 1995, now patented, Pat. No. US 5721354  
DT Utility  
EXNAM Primary Examiner: Stucker, Jeffrey; Assistant Examiner: Park, Hankyel T.  
LREP Cserr, Luann; Dunn, Tracy  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN 27 Drawing Figure(s); 53 Drawing Page(s)  
LN.CNT 2757

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided are novel Toledo and Towne human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and **compositions** for detecting HCMV infections and in immunogenic **compositions** for preventing HCMV infections.

L5 ANSWER 59 OF 98 USPATFULL  
AN 1999:75520 USPATFULL  
TI Stable purA vectors and uses therefor  
IN Brey, Robert N., Rochester, NY, United States  
Fulginiti, James P., Canandaigua, NY, United States  
Anilionis, Algis, Pittsford, NY, United States  
PA American Cyanamid Company, Madison, NJ, United States (U.S. corporation)  
PI US 5919663 19990706  
AI US 1995-380297 19950130 (8)  
RLI Continuation of Ser. No. US 1994-204903, filed on 2 Mar 1994, now abandoned which is a continuation of Ser. No. US 1991-695706, filed on 3 May 1991, now abandoned  
DT Utility

EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Brusca, John S.  
LREP Hamilton, Brook, Smith & Reynolds, P.C.  
CLMN Number of Claims: 41  
ECL Exemplary Claim: 8  
DRWN 13 Drawing Figure(s); 9 Drawing Page(s)  
LN.CNT 1390

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to a complementation system for the selection and maintenance of expressed genes in bacterial hosts. The invention provides stable vectors which can be selected and maintained by complementation of chromosomal deletion mutations of *purA* (adenylosuccinate synthetase), obviating the use of antibiotic resistance genes. This system is useful in production organisms during fermentation and in live **vaccine** bacteria, such as attenuated *Salmonella typhi*. This system allows for selection of chromosomal integrants and for selection and stable plasmid maintenance in the vaccinated host without application of external selection pressure.

L5 ANSWER 60 OF 98 USPATFULL

AN 1999:75477 USPATFULL

TI Heat shock protein HSP72 of *Streptococcus pneumoniae*

IN Brodeur, Bernard R., Sillery, Canada

Martin, Denis, St.-Augustin, Canada

Hamel, Josee, Sillery, Canada

PA Biochem Vaccines Inc., Ste-Foy, Canada (non-U.S. corporation)

PI US 5919620 19990706

AI US 1995-472534 19950607 (8)

DT Utility

EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Swartz, Rodney P.

LREP Foley & Lardner

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN 20 Drawing Figure(s); 14 Drawing Page(s)

LN.CNT 2571

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A heat shock protein of *Streptococcus pneumoniae* named HSP72 and immunologically related polypeptides, the nucleotide and derived amino acid sequences of HSP72 (SEQ ID NO:4; SEQ ID NO:5), antibodies that bind to HSP72, and recombinant DNA methods for the production of HSP72 and immunologically related polypeptides. The polypeptides, DNA sequences and antibodies of this invention provide new means for the diagnosis, prevention and/or **treatment** of disease.

L5 ANSWER 61 OF 98 USPATFULL

AN 1999:43372 USPATFULL

TI Methods of culturing and assaying a virus in a specimen

IN Huang, Yung T., Richmond Heights, OH, United States

PA University Hospitals of Cleveland, Cleveland, OH, United States (U.S. corporation)

PI US 5891624 19990406

AI US 1997-868091 19970603 (8)

RLI Division of Ser. No. US 1995-578189, filed on 29 Dec 1995

DT Utility

EXNAM Primary Examiner: Smith, Lynette F.; Assistant Examiner: Nelson, Brett

LREP Renner, Otto, Boisselle & Sklar, P.L.L.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 7 Drawing Figure(s); 4 Drawing Page(s)

LN.CNT 825

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a method for culturing a virus including the steps of (A) providing cells from a cell line susceptible to infection by the virus and a specimen; (B) treating the cells with a compound of

formula  $RC(O)Q$ , wherein Q is R, OR, OX or X, each R is independently hydrogen or a hydrocarbyl group containing 1 to about 10 carbon atoms and wherein X is hydrogen or a cation; (C) inoculating the treated cells with the specimen; and (D) incubating the inoculated cells to allow viral growth to proceed.

L5 ANSWER 62 OF 98 USPTFLL  
AN 1999:33800 USPTFLL  
TI ASPS  
IN Brown, James R, Berwyn, PA, United States  
Lawlor, Elizabeth J, Malvern, PA, United States  
Reichard, Raymond W, Quakertown, PA, United States  
PA Smithkline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)  
PI US 5882892 19990316  
AI US 1997-899244 19970723 (8)  
DT Utility  
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Duffy, Patricia A.  
LREP Gimmi, Edward R.; King, William T.; Jackson, Arthur E.  
CLMN Number of Claims: 19  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1521

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides aspS polypeptides and DNA (RNA) encoding aspS polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing aspS polypeptides to screen for antibacterial compounds.

L5 ANSWER 63 OF 98 USPTFLL  
AN 1999:33558 USPTFLL  
TI Peptide compounds  
IN Toth, Istvan, Middlesex, United Kingdom  
Gibbons, William Anthony, Kennington, United Kingdom  
PA The School of Pharmacy, University of London, United Kingdom (non-U.S. corporation)  
PI US 5882645 19990316  
WO 9402506 19940203  
AI US 1995-374560 19950313 (8)  
WO 1993-GB1558 19930723  
19950313 PCT 371 date  
19950313 PCT 102(e) date  
PRAI GB 1992-15780 19920724  
DT Utility  
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Ashton, Rosemary  
LREP Ostrolenk, Faber, Gerb & Soffen, LLP  
CLMN Number of Claims: 16  
ECL Exemplary Claim: 1  
DRWN 8 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 1491

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Synthetic peptides are widely used to generate antibodies. To induce high antibody response, it is known to conjugate the peptide to a carrier protein (e.g. KLH, BSA) or to incorporate it into polylysine to form a multiple antigenic peptide. Anchors may be built in which are based on fatty acids. According to the invention there is provided a novel lipidic amino acid based anchor system which can maximally enhance the antigenicity of a short synthetic peptide. These novel compounds are entirely peptide-based and may therefore be produced automatically by some step wise peptide synthesis, preferably solid phase step wise peptide synthesis. According to the invention there is also provided such a process.

L5 ANSWER 64 OF 98 USPATFULL  
AN 1999:4385 USPATFULL  
TI Hiss  
IN Brown, James R., Berwyn, PA, United States  
Lawlor, Elizabeth J, Malvern, PA, United States  
Reichard, Raymond W, Quakertown, PA, United States  
PA SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S.  
corporation)  
PI US 5858720 19990112  
AI US 1997-899028 19970723 (8)  
DT Utility  
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Duffy, Patricia  
A.  
LREP Gimmi, Edward R.; King, William T.; Jackson, Arthur E.  
CLMN Number of Claims: 19  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1446

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides hisS polypeptides and DNA (RNA) encoding hisS  
polypeptides and methods for producing such polypeptides by recombinant  
techniques. Also provided are methods for utilizing hisS polypeptides to  
screen for antibacterial compounds.

L5 ANSWER 65 OF 98 USPATFULL  
AN 1999:1233 USPATFULL  
TI Ichimeric papillomavirus-like particles  
IN Lowy, Douglas R., Bethesda, MD, United States  
Schiller, John T., Silver Spring, MD, United States  
Greenstone, Heather, Silver Spring, MD, United States  
PA The United States of America as represented by the Department of Health  
and Human Services, Washington, DC, United States (U.S. government)  
PI US 5855891 19990105  
AI US 1997-781084 19970109 (8)  
RLI Division of Ser. No. US 1994-319467, filed on 6 Oct 1994, now patented,  
Pat. No. US 5618536 which is a continuation-in-part of Ser. No. US  
1993-32869, filed on 16 Mar 1993, now patented, Pat. No. US 5437951  
which is a continuation-in-part of Ser. No. US 1992-941371, filed on 3  
Apr 1992  
DT Utility  
EXNAM Primary Examiner: Achutamurthy, Ponnathapura; Assistant Examiner: Park,  
Hankyel T.  
LREP Knobbe, Martens, Olson & Bear, LLP  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 992

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a papillomavirus-like particle having  
conformational epitopes comprising a papillomavirus L1 fusion product  
and, optionally, a papillomavirus L2 product; and related DNA molecules,  
host cells, and methods.

L5 ANSWER 66 OF 98 USPATFULL  
AN 1998:156922 USPATFULL  
TI Producing immunogenic constructs using soluble carbohydrates activated  
via organic cyanylating reagents  
IN Lees, Andrew, Silver Spring, MD, United States  
PA Henry M. Jackson Foundation for the Advancement of Military Medicine,  
Rockville, MD, United States (U.S. corporation)  
PI US 5849301 19981215  
AI US 1995-482666 19950607 (8)  
RLI Continuation-in-part of Ser. No. US 1995-408717, filed on 22 Mar 1995,  
now patented, Pat. No. US 5651971 which is a continuation-in-part of



Ser. No. US 1993-124491, filed on 22 Sep 1993, now abandoned  
DT Utility  
EXNAM Primary Examiner: Achutamurthy, Ponnathapura  
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.  
CLMN Number of Claims: 24  
ECL Exemplary Claim: 1  
DRWN 17 Drawing Figure(s); 11 Drawing Page(s)  
LN.CNT 2085

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a process for producing an immunogenic construct comprising activating at least one first carbohydrate-containing moiety with CDAP, CTEA or pNPC, and covalently joining the activated first moiety to a second moiety. Preferably, the first moiety is a polysaccharide and the second moiety is a protein. Immunogenic constructs are prepared by this process using either direct or indirect conjugation of the first and second moieties.

L5 ANSWER 67 OF 98 USPATFULL

AN 1998:150467 USPATFULL

TI Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for **vaccines**

IN Ladd, Anna Efim, Brooklyn, NY, United States

Wang, Chang Yi, Cold Spring Harbor, NY, United States

Zamb, Timothy Joseph, Stony Brook, NY, United States

PA United Biomedical, Inc., Hauppauge, NY, United States (U.S. corporation)

PI US 5843446 19981201

AI US 1995-488351 19950607 (8)

RLI Division of Ser. No. US 1995-446692, filed on 5 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-229275, filed on 14 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-57166, filed on 27 Apr 1993, now abandoned

DT Utility

EXNAM Primary Examiner: Smith, Lynette F.

LREP Morgan & Finnegan, LLP

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 39 Drawing Figure(s); 37 Drawing Page(s)

LN.CNT 4050

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to immunogenic luteinizing hormone releasing hormone (LHRH) peptides that lead to suppression of LHRH activity in males or females. These peptides are useful for inducing infertility and for treating prostatic hyperplasia, androgen-dependent carcinoma, prostatic carcinoma and testicular carcinoma in males. In females, the peptides are useful for treating endometriosis, benign uterine tumors, recurrent functional ovarian cysts and (severe) premenstrual syndrome as well as prevention or **treatment** of estrogen-dependent breast cancer. The subject peptides contain a helper T cell epitope and have LHRH at the C terminus. The helper T cell epitope aids in stimulating the immune response against LHRH. The peptides, optionally contain an invasin domain which acts as a general immune stimulator.

In another aspect this invention relates to immunogenic synthetic peptides having an invasin domain, a helper T cell epitope and a peptide hapten and methods of using these peptides to treat disease or provide protective immunity. The peptide haptens of the invention include LHRH, amylin, gastrin, gastrin releasing peptide, IgE CH4 peptide, **Chlamydia** MOMP peptides, HIV V3 peptides and Plasmodium berghei.

L5 ANSWER 68 OF 98 USPATFULL

AN 1998:147025 USPATFULL

TI **Vaccine** comprising anti-idiotypic antibody to **chlamydia** GLXA and process

IN MacDonald, Alex Bruce, Amherst, MA, United States

An, Ling-Ling, La Jolla, CA, United States  
Sutton-Stuart, Elizabeth, Amherst, MA, United States  
Whittum-Hudson, Judith A., Elkton, MD, United States  
PA Johns Hopkins University, United States (U.S. corporation)  
University of Massachusetts, United States (U.S. corporation)  
PI US 5840297 19981124  
AI US 1993-34572 19930319 (8)  
DT Utility  
EXNAM Primary Examiner: Loring, Susan A.  
LREP Cook, Paul J.  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 5  
DRWN 17 Drawing Figure(s); 9 Drawing Page(s)  
LN.CNT 2015  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A genus specific **chlamydia vaccine** is provided which comprises an anti-idiotypic antibody capable of producing in an animal an anti-anti-idiotypic antibody which recognizes a glycoplipid exoantigen (GLXA) of **chlamydia**. The **vaccine** is produced by producing an idiotypic antibody to GLXA which, in turn, is utilized to produce the anti-idiotypic antibody comprising the **vaccine**.

L5 ANSWER 69 OF 98 USPATFULL  
AN 1998:124386 USPATFULL  
TI **Chlamydia** major outer membrane protein  
IN Agabian, Nina, San Francisco, CA, United States  
Stephens, Richard, Oakland, CA, United States  
Kuo, Cho-Chou, Seattle, WA, United States  
Mullenbach, Guy, Oakland, CA, United States  
PA Washington Research Foundation, Seattle, WA, United States (U.S. corporation)  
Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
PI US 5821055 19981013  
AI US 1995-468451 19950606 (8)  
RLI Continuation of Ser. No. US 1993-144095, filed on 28 Oct 1993, now abandoned which is a continuation of Ser. No. US 1991-691639, filed on 25 Apr 1991, now abandoned which is a continuation of Ser. No. US 1986-818523, filed on 13 Jan 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-692001, filed on 14 Jan 1985, now abandoned  
DT Utility  
EXNAM Primary Examiner: Zitomer, Stephanie W.; Assistant Examiner: Rees, Dianne  
LREP Townsend and Townsend and Crew LLP  
CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN 8 Drawing Figure(s); 8 Drawing Page(s)  
LN.CNT 721  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and **compositions** are provided for the production of a polypeptide which is immunologically cross-reactive with a naturally-occurring major outer membrane protein (MOMP) of **Chlamydia trachomatis**. A DNA construct including a replication system recognized by E. coli, and an MOMP gene under the transcriptional control of a .beta.-galactosidase promoter and terminator is provided.

Recombinant phage .lambda.gt11/L2/33 was deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, on Jan. 10, 1985 and granted accession no. 40157. L2 B9-F DNA was deposited at the American Type Culture Collection on Dec. 31, 1985, and granted accession No. 40217.

L5 ANSWER 70 OF 98 USPATFULL

AN 1998:108030 USPATFULL  
TI Sperm as immunogen carriers  
IN Scofield, Virginia L., 372 Redwood Dr., Pasadena, CA, United States  
91105  
PI US 5804191 19980908  
AI US 1997-865724 19970530 (8)  
RLI Continuation-in-part of Ser. No. US 1995-406299, filed on 17 Mar 1995,  
now abandoned which is a continuation-in-part of Ser. No. US  
1994-343008, filed on 21 Nov 1994, now abandoned  
DT Utility  
EXNAM Primary Examiner: Degen, Nancy; Assistant Examiner: Sandals, William  
LREP Knobbe, Martens, Olson & Bear, LLP  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 6 Drawing Page(s)  
LN.CNT 1179

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Vaccine compositions**, contraceptives, and gene  
therapy delivery vectors are disclosed in which sperm cells or  
components thereof are used to deliver immunogens or selected gene  
sequences to target cells both in vitro and in vivo. Methods of making  
the **vaccine compositions**, contraceptives, and gene  
therapy delivery formulations are disclosed. Methods of vaccination,  
contraception, and gene therapy are also disclosed.

L5 ANSWER 71 OF 98 USPATFULL  
AN 1998:88700 USPATFULL  
TI Adeno-associated virus materials and methods  
IN Johnson, Philip R., Gahanna, OH, United States  
PA Children's Hospital, Inc., Columbus, OH, United States (U.S.  
corporation)  
PI US 5786211 19980728  
AI US 1995-475391 19950607 (8)  
RLI Division of Ser. No. US 1994-254358, filed on 6 Jun 1994, now patented,  
Pat. No. US 5658785  
DT Utility  
EXNAM Primary Examiner: Ketter, James; Assistant Examiner: Yucel, Irem  
LREP Marshall, O'Toole, Gerstein, Murray & Borun  
CLMN Number of Claims: 1  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 911

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides adeno-associated virus (AAV) materials  
and methods which are useful for DNA delivery to cells. More  
particularly, the invention provides recombinant AAV (rAAV) genomes,  
methods for packaging rAAV genomes, stable host cell lines producing  
rAAV and methods for delivering genes of interest to cells utilizing the  
rAAV. Particularly disclosed are rAAV useful in generating immunity to  
human immunodeficiency virus-1 and in therapeutic gene delivery for  
**treatment** of neurological disorders.

L5 ANSWER 72 OF 98 USPATFULL  
AN 1998:82562 USPATFULL  
TI Method and system for enhanced production of commercially important  
exoproteins in gram-positive bacteria  
IN Kontinen, Vesa, Helsinki, Finland  
Sarvas, Matti, Helsinki, Finland  
PA The Finnish National Public Health Institute (KTL), Helsinki, Finland  
(non-U.S. corporation)  
PI US 5780261 19980714  
WO 9419471 19940901  
AI US 1996-507391 19960708 (8)  
WO 1994-FI72 19940225

19960708 PCT 371 date  
19960708 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1993-24154, filed on 26 Feb 1993,  
now abandoned

DT Utility

EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Masood, Khalid

LREP Meyer, Esq., Virginia H.

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1134

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a method and expression system for enhancing secretion of hyperproduced homologous and heterologous exoproteins in gram-positive bacteria such as *Bacillus* sp. The method and system comprise overproduction of PrsA protein in gram-positive bacterial host capable of also overproducing at least one exoprotein of interest. Use of the method and system of the invention results in greatly enhanced secretion of the synthesized exoproteins into the growth medium. Once in the growth medium these secreted exoproteins can be recovered and purified in a straightforward manner.

L5 ANSWER 73 OF 98 USPATFULL

AN 1998:72737 USPATFULL

TI **Chlamydia** major outer membrane protein

IN Agabian, Nina, San Francisco, CA, United States

Stephens, Richard, Oakland, CA, United States

Kuo, Cho-Chou, Seattle, WA, United States

Mullenbach, Guy, Oakland, CA, United States

PA Washington Research Foundation, Seattle, WA, United States (U.S. corporation)

Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

PI US 5770714 19980623

AI US 1995-466814 19950606 (8)

RLI Division of Ser. No. US 1993-144095, filed on 28 Oct 1993, now abandoned which is a continuation of Ser. No. US 1991-691639, filed on 25 Apr 1991, now abandoned which is a continuation of Ser. No. US 1986-818523, filed on 13 Jan 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-692001, filed on 14 Jan 1985, now abandoned

DT Utility

EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Rees, Dianne

LREP Townsend and Townsend and Crew LLP

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN 8 Drawing Figure(s); 8 Drawing Page(s)

LN.CNT 696

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and **compositions** are provided for the production of a polypeptide which is immunologically cross-reactive with a naturally-occurring major outer membrane protein (MOMP) of **Chlamydia trachomatis**. A DNA construct including a replication system recognized by *E. coli*, and an MOMP gene under the transcriptional control of a  $\beta$ -galactosidase promoter and terminator is provided. Recombinant phage  $\lambda$ .gt11/L2/33 was deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, on Jan. 10, 1985 and granted accession no. 40157. L2 B9-F DNA was deposited at the American Type Culture Collection on Dec. 31, 1985, and granted accession No. 40217.

L5 ANSWER 74 OF 98 USPATFULL

AN 1998:61171 USPATFULL

TI Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for **vaccines**

IN Ladd, Anna Efim, Brooklyn, NY, United States

Wang, Chang Yi, Cold Spring Harbor, NY, United States  
Zamb, Timothy Joseph, Stony Brook, NY, United States  
PA United Biomedical, Inc., Hauppauge, NY, United States (U.S. corporation)  
PI US 5759551 19980602  
WO 9425060 19941110  
AI US 1995-446692 19951226 (8)  
WO 1994-US4832 19940428  
19951226 PCT 371 date  
19951226 PCT 102(e) date  
RLI Division of Ser. No. US 1995-488351, filed on 7 Jun 1995  
DT Utility  
EXNAM Primary Examiner: Smith, Lynette F.  
LREP Morgan & Finnegan, LLP  
CLMN Number of Claims: 15  
ECL Exemplary Claim: 1  
DRWN 37 Drawing Figure(s); 37 Drawing Page(s)  
LN.CNT 3752

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to immunogenic luteinizing hormone releasing hormone (LHRH) peptides that lead to suppression of LHRH activity in males or females. When male rats are immunized with these peptides, serum testosterone drops and androgen-dependent organs atrophy significantly. These peptides are useful for inducing infertility and for treating prostatic hyperplasia, androgen-dependent carcinoma, prostatic carcinoma and testicular carcinoma in males. In females, the peptides are useful for treating endometriosis, benign uterine tumors, recurrent functional ovarian cysts and (severe) premenstrual syndrome as well as prevention or **treatment** of estrogen-dependent breast cancer. The subject peptides contain a helper T cell epitope and have LHRH at the C terminus. The helper T cell epitope aids in stimulating the immune response against LHRH. The peptides, optionally contain an invasin domain which acts as a general immune stimulator. In another aspect this invention relates to immunogenic synthetic peptides having an invasin domain, a helper T cell epitope and a peptide hapten and methods of using these peptides to treat disease or provide protective immunity. The peptide haptens of the invention include LHRH, amylin, gastrin, gastrin releasing peptide, IgE CH4 peptide, **Chlamydia** MOMP peptides, HIV V3 peptides and Plasmodium berghei.

L5 ANSWER 75 OF 98 USPATFULL  
AN 1998:24927 USPATFULL  
TI Polypeptides useful in prevention of **chlamydia** infection  
IN Daniels, Eddie K., Hastings, NE, United States  
Woollen, Neal E., Harvard, NE, United States  
PA The United States of America as represented by the Secretary of Agriculture, Washington, DC, United States (U.S. government)  
PI US 5725863 19980310  
AI US 1991-756346 19910906 (7)  
DT Utility  
EXNAM Primary Examiner: Cunningham, Thomas M.  
LREP Silverstein, M. Howard; Ribando, Curtis P.; Fado, John D.  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 711

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a polypeptide **vaccine** and method to immunize subjects against **Chlamydia**. In particular, this invention relates to essentially pure polypeptides of **Chlamydia** psittaci strain DD-34 ranging from about 40 to 140 kilodaltons in a pharmaceutically acceptable carrier. These **compositions** are used to immunize several species of animals against **Chlamydia**. More specifically, this invention relates to the discovery of a highly immunogenic essentially pure polypeptide of

**Chlamydia** psittaci strain DD-34 having a molecular weight of about 96 kilodaltons.

L5 ANSWER 76 OF 98 USPATFULL  
AN 1998:19818 USPATFULL  
TI Human cytomegalovirus DNA sequences  
IN Spaete, Richard, Belmont, CA, United States  
Cha, Tai-An, San Ramon, CA, United States  
PA Aviron, Mountain View, CA, United States (U.S. corporation)  
PI US 5721354 19980224  
AI US 1995-414926 19950331 (8)  
DT Utility  
EXNAM Primary Examiner: Adams, Donald E.; Assistant Examiner: Park, Hankyel T.  
LREP Cserr, Luann; Dunn, Tracy  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN 53 Drawing Figure(s); 53 Drawing Page(s)  
LN.CNT 2025

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided are novel Toledo and Towne human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and **compositions** for detecting HCMV infections and in immunogenic **compositions** for preventing HCMV infections.

L5 ANSWER 77 OF 98 USPATFULL  
AN 1998:14646 USPATFULL  
TI Method for diagnosing a patient for **chlamydia**  
IN MacDonald, Alex Bruce, Amherst, MA, United States  
Stuart, Elizabeth S., Amherst, MA, United States  
An, Ling Ling, La Jolla, CA, United States  
Whipkey, Myron D., Portland, ME, United States  
PA Animal House, Inc., Portland, ME, United States (U.S. corporation)  
PI US 5716793 19980210  
AI US 1995-406113 19950317 (8)  
RLI Continuation-in-part of Ser. No. US 1993-34572, filed on 19 Mar 1993  
DT Utility  
EXNAM Primary Examiner: Spiegel, Carol A.  
LREP Cook, Paul J.  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN 17 Drawing Figure(s); 9 Drawing Page(s)  
LN.CNT 1933

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of detecting **chlamydia** in a extracellular sample is provided which comprises contacting the sample with an idiotypic antibody to GLXA to form an immunocomplex and detecting the immunocomplex.

L5 ANSWER 78 OF 98 USPATFULL  
AN 97:112166 USPATFULL  
TI Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents  
IN Lees, Andrew, Silver Spring, MD, United States  
PA Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, United States (U.S. corporation)  
PI US 5693326 19971202  
AI US 1995-456694 19950601 (8)  
DCD 20120322  
RLI Continuation of Ser. No. US 1995-408717, filed on 22 Mar 1995 which is a continuation-in-part of Ser. No. US 1993-124491, filed on 22 Sep 1993, now abandoned  
DT Utility  
EXNAM Primary Examiner: Achutamurthy, Ponnathapura  
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.

CLMN Number of Claims: 19  
ECL Exemplary Claim: 1,13  
DRWN 17 Drawing Figure(s); 11 Drawing Page(s)  
LN.CNT 1844

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a process for producing an immunogenic construct comprising activating at least one first carbohydrate-containing moiety with CDAP, and covalently joining the activated first moiety to a second moiety. Preferably, the first moiety is a polysaccharide and the second moiety is a protein. Immunogenic constructs are prepared by this process using either direct or indirect conjugation of the first and second moieties.

L5 ANSWER 79 OF 98 USPATFULL

AN 97:88734 USPATFULL

TI Selective maintenance of a recombinant gene in a population of **vaccine** cells

IN Curtiss, III, Roy, St. Louis, MO, United States

PA Washington University, St. Louis, MO, United States (U.S. corporation)

PI US 5672345 19970930

AI US 1995-402308 19950310 (8)

RLI Continuation of Ser. No. US 1992-990361, filed on 15 Dec 1992, now abandoned which is a continuation of Ser. No. US 1988-251304, filed on 3 Oct 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-106072, filed on 7 Oct 1987, now abandoned

DT Utility

EXNAM Primary Examiner: Vogel, Nancy T.

LREP Howell & Haferkamp, L.C.

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN 18 Drawing Figure(s); 18 Drawing Page(s)

LN.CNT 2348

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention encompasses methods of maintaining desired recombinant genes in a genetic population of cells expressing the recombinant gene. The methods utilize mutant cells which are characterized by a lack of a functioning native gene encoding an enzyme which is essential for cell survival, wherein this enzyme catalyzes a step in the biosynthesis of an essential cell wall structural component and the presence of a first recombinant gene encoding an enzyme which is a functional replacement for the native enzyme, wherein the first recombinant gene cannot replace the defective chromosomal gene. The first recombinant gene is structurally linked to a second recombinant gene encoding a desired product. Loss of the first recombinant gene causes the cells to lyse when the cells are in an environment where a product due to the expression of the first recombinant gene is absent. The invention also encompasses methods of creating and isolating mutant cells with the above characteristics. The cells of the invention are useful for commercial production of desired products, for components of **vaccines** for immunizing individuals, and for release into the environment.

L5 ANSWER 80 OF 98 USPATFULL

AN 97:73593 USPATFULL

TI Acridinone derivative, **compositions** containing same and a method for using same to treat **Chlamydia trachomatis**

IN Chizhov, Novomir Pavlovich, St.-Petersburg, Russian Federation

Kupchinsky, Roald Antonovich, St.-Petersburg, Russian Federation

Alekseeva, Ljudmila Evgenievna, St.-Petersburg, Russian Federation

Kovalenko, Aleksei Leonidovich, St.-Petersburg, Russian Federation

Borisova, Margarita Alekseevna, St.-Petersburg, Russian Federation

PA Limited Liability Partnership "POLYSAN", St-Petersburg, Russian Federation (non-U.S. corporation)

PI US 5658886 19970819

WO 9422837 19941013  
 AI US 1994-351385 19941207 (8)  
 WO 1994-RU32 19940223  
 19941207 PCT 371 date  
 19941207 PCT 102(e) date  
 PRAI RU 1993-93017260 19930401  
 DT Utility  
 EXNAM Primary Examiner: Wilson, James O.  
 LREP Marshall, O'Toole, Gerstein, Murray & Borun  
 CLMN Number of Claims: 3  
 ECL Exemplary Claim: 1,3  
 DRWN No Drawings  
 LN.CNT 483  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The claims cover a bioactive compound N-methyl-N-.alpha.-D-glucopyranosil-ammonium-2-acridone-9-on-10-yl-acetate designated CYCLOFERONE which was obtained by chemical synthesis and is a heterocyclic compound. Specifically CYCLOFERONE is an acridanone derivative of formula ##STR1## CYCLOFERONE exhibits interferonogenic, anti-vital (including anti-HIV), anti-parasitic, anti-promotive, and radioprotective effects.

L5 ANSWER 81 OF 98 USPATFULL  
 AN 97:70717 USPATFULL  
 TI Oral **vaccine** comprising anti-idiotypic antibody to **chlamydia** glycolipid exoantigen and process  
 IN MacDonald, Alex Bruce, Hatfield, MA, United States  
 Whittum-Hudson, Judith A., Elkton, MD, United States  
 Saltzman, William Mark, Baltimore, MD, United States  
 PA The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)  
 University of Massachusetts, Amherst, MA, United States (U.S. corporation)  
 PI US 5656271 19970812  
 AI US 1995-466752 19950606 (8)  
 RLI Continuation of Ser. No. US 1994-213863, filed on 16 Mar 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-34572, filed on 19 Mar 1993  
 DT Utility  
 EXNAM Primary Examiner: Loring, Susan A.  
 CLMN Number of Claims: 15  
 ECL Exemplary Claim: 1  
 DRWN 19 Drawing Figure(s); 10 Drawing Page(s)  
 LN.CNT 2188  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB A genus specific **chlamydia** oral or injectable **vaccine** is provided which comprises an anti-idiotypic antibody capable of producing in an animal an anti-idiotypic antibody or Fab fragment thereof enclosed in microspheres formed of a pharmacologically acceptable polymer is capable of producing in an animal an anti-anti-idiotypic immune response (serum antibody, secretory antibody or T-cell response) which recognizes a glycolipid exoantigen (GLXA) of **chlamydia**. The oral or injectable **vaccine** is produced from an idiotypic antibody to GLXA which, in turn, is utilized to produce the anti-idiotypic antibody.

L5 ANSWER 82 OF 98 USPATFULL  
 AN 97:65865 USPATFULL  
 TI Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents  
 IN Lees, Andrew, Silver Spring, MD, United States  
 PA Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, United States (U.S. corporation)  
 PI US 5651971 19970729



AI US 1995-408717 19950322 (8)  
RLI Continuation-in-part of Ser. No. US 1993-124491, filed on 22 Sep 1993,  
now abandoned  
DT Utility  
EXNAM Primary Examiner: Achutamurthy, Ponnathapura  
LREP Finnegan, Henderson, Farabow, Garrett & Dunner L.L.P.  
CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN 17 Drawing Figure(s); 11 Drawing Page(s)  
LN.CNT 1837

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a process for producing an immunogenic  
construct comprising activating at least one first carbohydrate-  
containing moiety with CDAP, and covalently joining the activated first  
moiety to a second moiety. Preferably, the first moiety is a  
polysaccharide and the second moiety is a protein. Immunogenic  
constructs are prepared by this process using either direct or indirect  
conjugation of the first and second moieties.

L5 ANSWER 83 OF 98 USPATFULL

AN 97:40647 USPATFULL

TI Detection of antibodies against **Chlamydia trachomatis**  
pgp3 antigen in patient sera by enzyme-linked immunosorbent assay

IN Ratti, Giulio, Siena, Italy

PA Biocine S.p.A., Italy (non-U.S. corporation)

PI US 5629167 19970513

AI US 1994-229980 19940419 (8)

DT Utility

EXNAM Primary Examiner: Knode, Marian C.; Assistant Examiner: Duffy, Patricia  
A.

LREP Woodcock, Washburn, Kurtz, Mackiewicz & Norris; McClung, Barbara G.;  
Blackburn, Robert P.

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 1258

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A new recombinant form of the plasmid-encoded protein pgp3 from C.  
trachomatis, serotype D, was purified by ion exchange column  
chromatography and shown to be suitable for quantitative immunoassay on  
clinical samples in an ELISA format.

L5 ANSWER 84 OF 98 USPATFULL

AN 97:29201 USPATFULL

TI Chimeric papillomavirus-like particles

IN Lowy, Douglas R., Bethesda, MD, United States

Schiller, John T., Silver Spring, MD, United States

Greenstone, Heather, Silver Spring, MD, United States

PA The United States of America as represented by the Department of Health  
and Human Services, Washington, DC, United States (U.S. government)

PI US 5618536 19970408

AI US 1994-319467 19941006 (8)

RLI Continuation-in-part of Ser. No. US 1993-32869, filed on 16 Mar 1993,  
now patented, Pat. No. US 5437951 which is a continuation-in-part of  
Ser. No. US 1992-941371, filed on 3 Sep 1992

DT Utility

EXNAM Primary Examiner: Mosher, Mary E.; Assistant Examiner: Chen, Michael C.

LREP Knobbe, Martens, Olson & Bear, LLP

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1105

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a papillomavirus-like particle,

characterized as having conformational epitopes, comprising a papillomavirus L1 product and a papillomavirus L2 fusion product; and related synthetic DNA molecules, host cells, methods and **vaccines**.

L5 ANSWER 85 OF 98 USPATFULL  
AN 96:120795 USPATFULL  
TI Fusion proteins  
IN Lipscombe, Martin J., Cambridge, United Kingdom  
Charles, Ian G., Beckenham, United Kingdom  
Fairweather, Neil F., Beckenham, United Kingdom  
PA Glaxo Wellcome Inc., Research Triangle Park, NC, United States (U.S. corporation)  
PI US 5589384 19961231  
AI US 1994-237716 19940502 (8)  
RLI Continuation of Ser. No. US 1992-896003, filed on 11 Jun 1992, now abandoned  
PRAI GB 1991-12553 19910611  
DT Utility  
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Bugaisky, Gabriele E.  
LREP Nixon & Vanderhye P.C.  
CLMN Number of Claims: 25  
ECL Exemplary Claim: 1  
DRWN 8 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 773  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A fusion protein suitable for use as a **vaccine** comprises an amino acid sequence having biological activity which is fused via an intervening hinge comprising from two to eight glycine-proline repeats to the C-terminus of sufficient of the amino acid sequence of a B subunit of an enterotoxin which is capable of ADP-ribosylation of a GTPase.

L5 ANSWER 86 OF 98 USPATFULL  
AN 96:116111 USPATFULL  
TI Dual carrier immunogenic construct  
IN Mond, James J., Potomac, MD, United States  
Lees, Andrew, Baltimore, MD, United States  
PA Henry Jackson Foundation, Rockville, MD, United States (U.S. corporation)  
PI US 5585100 19961217  
AI US 1995-402565 19950313 (8)  
RLI Continuation of Ser. No. US 1993-126017, filed on 24 Sep 1993, now abandoned which is a continuation of Ser. No. US 1992-834067, filed on 11 Feb 1992, now abandoned  
DT Utility  
EXNAM Primary Examiner: Housel, James C.; Assistant Examiner: Krsek-Staples, Julie  
LREP Finnegan, Henderson, Farabow, Garrett and Dunner, L.L.P.  
CLMN Number of Claims: 31  
ECL Exemplary Claim: 1  
DRWN 14 Drawing Figure(s); 14 Drawing Page(s)  
LN.CNT 1143

AB A dual carrier immunogenic construct comprised of at least one primary carrier comprising large molecular weight molecule of greater than a 70 KD molecular weight and at least one secondary carrier comprising a T-dependent antigen conjugated to a primary carrier. The dual carrier immunogenic construct may further comprise moieties such as haptens and antigens. Such immunogenic constructs are suitable for use in the diagnosis, **treatment**, and prevention of diseases.

L5 ANSWER 87 OF 98 USPATFULL  
AN 95:52114 USPATFULL

TI **Vaccines** containing avirulent phop-type microorganisms  
IN Curtiss, III, Roy, St. Louis, MO, United States  
Galan, Jorge, St. Louis, MO, United States  
PA Washington University, St. Louis, MO, United States (U.S. corporation)  
PI US 5424065 19950613  
AI US 1992-981935 19921119 (7)  
RLI Continuation of Ser. No. US 1989-331979, filed on 31 Mar 1989  
DT Utility  
EXNAM Primary Examiner: Sidberry, Hazel F.  
LREP Rogers, Howell & Haferkamp  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)  
LN.CNT 1648

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The phoP gene and its equivalents are of a type which have "global regulation of pathogenicity", i.e., they coordinately regulate a number of genes including those that encode bacterial virulence factors. In Salmonella, the phoP gene product also controls the expression of non-specific acid phosphatase from the phoN gene. A central feature of the invention are microorganisms which are avirulent as a result, in whole or in part, of a mutation in phoP, but which retain their immunogenicity. These cells are suitable as components of live **vaccines**.

L5 ANSWER 88 OF 98 USPATFULL

AN 94:104475 USPATFULL

TI Method for mycoplasma detection in a biological sample

IN Baseman, Joel B., San Antonio, TX, United States

Su, C. J., San Antonio, TX, United States

Dallo, S. F., San Antonio, TX, United States

PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

PI US 5369005 19941129

AI US 1992-965055 19921022 (7)

RLI Continuation of Ser. No. US 1990-558886, filed on 27 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1987-118967, filed on 19 Nov 1987, now patented, Pat. No. US 5026636 which is a continuation-in-part of Ser. No. US 1987-4767, filed on 9 Jan 1987, now patented, Pat. No. US 4945041

DT Utility

EXNAM Primary Examiner: Parr, Margaret; Assistant Examiner: Sisson, Bradley L.

LREP Arnold, White & Durkee

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN 35 Drawing Figure(s); 26 Drawing Page(s)

LN.CNT 2114

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for detecting mycoplasma in a biological sample through the application of nucleic acid hybridization techniques. More specifically, the instant invention details a method of detecting a wide variety of mycoplasma in a biological sample by employing a polynucleotide segment encoding a portion of M. pneumoniae P1 polypeptide.

L5 ANSWER 89 OF 98 USPATFULL

AN 94:28876 USPATFULL

TI Method for purifying an outer membrane protein of Haemophilus influenzae

IN Murphy, Timothy F., East Amherst, NY, United States

Apicella, Michael A., Pendleton, NY, United States

PA Research Foundation of State University of New York, Albany, NY, United States (U.S. corporation)

PI US 5300632 19940405

AI US 1991-807049 19911212 (7)

RLI Continuation-in-part of Ser. No. US 1989-330229, filed on 29 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-92948, filed on 8 Oct 1987, now patented, Pat. No. US 5173294 And a continuation-in-part of Ser. No. US 1986-932872, filed on 18 Nov 1986, now abandoned

DT Utility

EXNAM Primary Examiner: Wityshyn, Michael G.; Assistant Examiner: Sayala, C.

LREP Nixon Hargrave Devans & Doyle

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN 13 Drawing Figure(s); 11 Drawing Page(s)

LN.CNT 1150

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for purification of a surface exposed, immunogenic outer membrane protein of Haemophilus influenzae which is conserved amongst strains. The protein, designated P6, is relatively free of detergent, contaminating RNA and undesirable cellular components.

In accordance with the present invention, there is provided a method for purifying an immunogenic outer membrane protein of H. influenzae consisting essentially of:

a) suspending H. influenzae micro-organisms by incubating the organisms in a detergent buffer to form an insoluble fraction comprising the outer membrane protein and peptidoglycan component and a soluble fraction comprising the remainder of the cellular components;

b) separating the insoluble fraction from the soluble fraction;

c) suspending the insoluble fraction in detergent buffer containing RNase and allowing for RNA digestion;

d) separating the insoluble fraction from the soluble fraction comprising the RNase and digested RNA;

e) solubilizing the insoluble fraction by heat-treating in a detergent-free buffer; and

f) separating the soluble fraction containing the purified outer membrane protein from the insoluble fraction containing the peptidoglycan component.

L5 ANSWER 90 OF 98 USPATFULL

AN 91:49574 USPATFULL

TI Contraceptive device

IN Zelson, Steve T., 209 Mulberry La., Larchmont, NY, United States 10538

PI US 5025800 19910625

AI US 1988-148568 19880126 (7)

DT Utility

EXNAM Primary Examiner: Rosenbaum, C. Fred; Assistant Examiner: Rose, Sharon

LREP Zelson, Steve T.

CLMN Number of Claims: 28

ECL Exemplary Claim: 1

DRWN 6 Drawing Figure(s); 8 Drawing Page(s)

LN.CNT 803

AB This invention relates to contraceptive devices. More particularly, this invention relates to novel contraceptive devices for males and females which provide immunological barriers to the spread of sexually transmitted diseases along with related methods to prevent the spread of these diseases.

L5 ANSWER 91 OF 98 USPATFULL

AN 89:30045 USPATFULL

TI Process for labeling single-stranded nucleic acids and hybridization probes

IN Watson, Robert M., Berkeley, CA, United States  
Sheldon, III, Edward L., Oakland, CA, United States  
Snead, Richard M., Oakland, CA, United States

PA Cetus Corporation, Emeryville, CA, United States (U.S. corporation)

PI US 4822731 19890418

AI US 1986-819490 19860109 (6)

DT Utility

EXNAM Primary Examiner: Nucker, Christine M.; Assistant Examiner: Krupen, Karen

LREP Kaster, Kevin R.; Hasak, Janet E.; Halluin, Albert P.

CLMN Number of Claims: 28

ECL Exemplary Claim: 1

DRWN 3 Drawing Figure(s); 3 Drawing Page(s)

LN.CNT 1526

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nucleic acids may be labeled by complexing the alkylating moiety of a labeling reagent into a single-stranded nucleic acid to form a complex and activating the complex to cause covalent bonding between the reagent and the nucleic acid. Preferably, the labeled nucleic acid is a single-stranded hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive. The labeling reagent is of the formula:

[A--[B--L

where A is an alkylating moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the alkylating and label moieties.

Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5',8-trimethylpsoralen moiety and L is biotin.

L5 ANSWER 92 OF 98 USPATFULL

AN 89:9403 USPATFULL

TI Carbamic acid ester useful for preparing a nucleic acid probe

IN Levenson, Corey H., Oakland, CA, United States  
Mullis, Kary B., Kensington, CA, United States

PA Cetus Corporation, Emeryville, CA, United States (U.S. corporation)

PI US 4803297 19890207

AI US 1987-72339 19870713 (7)

RLI Division of Ser. No. US 1986-888252, filed on 21 Jul 1986, now patented, Pat. No. US 4705886 which is a division of Ser. No. US 1985-791332, filed on 25 Oct 1985, now patented, Pat. No. US 4617261 which is a continuation-in-part of Ser. No. US 1984-683263, filed on 18 Dec 1984, now patented, Pat. No. US 4582789 which is a continuation-in-part of Ser. No. US 1984-591811, filed on 21 May 1984, now abandoned

DT Utility

EXNAM Primary Examiner: Lee, Mary C.; Assistant Examiner: Whittenbaugh, Robert C.

LREP Halluin, Albert P.; Hasak, Janet E.

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2072

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nucleic acids may be labeled by intercalating the alkylating intercalation moiety of a labeling reagent into a partially double-stranded nucleic acid to form a complex and activating the complex to cause covalent bonding between the reagent and the nucleic

acid. Preferably, the labeled nucleic acid is hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive. The labeling reagent is of the formula:

[A--[B--L

where A is an alkylating intercalation moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the intercalation and label moieties.

Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5',8-trimethylpsoralen moiety and L is biotin.

L5 ANSWER 93 OF 98 USPATFULL  
AN 88:40765 USPATFULL  
TI Precursor to nucleic acid probe  
IN Levenson, Corey H., Oakland, CA, United States  
Mullis, Kary B., Kensington, CA, United States  
PA Cetus Corporation, Emeryville, CA, United States (U.S. corporation)  
PI US 4754065 19880628  
AI US 1987-72536 19870713 (7)  
RLI Division of Ser. No. US 1986-888252, filed on 21 Jul 1986, now patented, Pat. No. US 4705886 which is a continuation-in-part of Ser. No. US 1985-791332, filed on 25 Oct 1985, now patented, Pat. No. US 4617261 which is a continuation-in-part of Ser. No. US 1984-683263, filed on 18 Dec 1984, now patented, Pat. No. US 4582789 which is a continuation-in-part of Ser. No. US 1984-591811, filed on 21 Mar 1984, now abandoned  
DT Utility  
EXNAM Primary Examiner: Schwartz, Richard A.  
LREP Halluin, Albert P.; Hasak, Janet E.  
CLMN Number of Claims: 2  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2120  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Nucleic acids may be labeled by intercalating the alkylating intercalation moiety of a labeling reagent into a partially double-stranded nucleic acid to form a complex and activating the complex to cause covalent bonding between the reagent and the nucleic acid. Preferably, the labeled nucleic acid is a hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive. The labeling reagent is of the formula:

[A] [B] L

where A is an alkylating intercalation moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the intercalation and label moieties.

Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5',8-trimethylpsoralen moiety and L is biotin.

L5 ANSWER 94 OF 98 USPATFULL  
AN 88:37773 USPATFULL  
TI Precursor to nucleic acid probe

IN Levenson, Corey H., Oakland, CA, United States  
Mullis, Kary B., Kensington, CA, United States  
PA Cetus Corporation, Emeryville, CA, United States (U.S. corporation)  
PI US 4751313 19880614  
AI US 1987-72531 19870713 (7)  
RLI Division of Ser. No. US 1986-888252, filed on 21 Jul 1986, now patented,  
Pat. No. US 4705886 And Ser. No. US 1985-791332, filed on 25 Oct 1985,  
now patented, Pat. No. US 4617261 which is a continuation-in-part of  
Ser. No. US 1984-683263, filed on 18 Dec 1984, now patented, Pat. No. US  
4582789 which is a continuation-in-part of Ser. No. US 1984-591811,  
filed on 21 Mar 1984, now abandoned  
DT Utility  
EXNAM Primary Examiner: Schwartz, Richard A.  
LREP Halluin, Albert P.; Hasak, Janet E.  
CLMN Number of Claims: 2  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2140

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nucleic acids may be labeled by intercalating the alkylating  
intercalation moiety of a labeling reagent into a partially  
double-stranded nucleic acid to form a complex and activating the  
complex to cause covalent bonding between the reagent and the nucleic  
acid. Preferably, the labeled nucleic acid is a hybridization probe for  
detecting nucleic acid sequences capable of hybridizing with a  
hybridizing region of the nucleic acid. Also preferably the label moiety  
is non-radioactive. The labeling reagent is of the formula:

[A][B]L

where A is an alkylating intercalation moiety, B is a divalent organic  
moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a  
number from 1 to 4, y is a number from 2 to 4, and L is a monovalent  
label moiety, wherein B is exclusive of any portion of the intercalation  
and label moieties.

Preferably A is a 4-methylene-substituted psoralen moiety, and most  
preferably A is a 4'-methylene-substituted-4,5',8-trimethylpsoralen  
moiety and L is biotin.

L5 ANSWER 95 OF 98 USPATFULL  
AN 87:78077 USPATFULL  
TI Precursor to nucleic acid probe  
IN Levenson, Corey H., Oakland, CA, United States  
Mullis, Kary B., Kensington, CA, United States  
PA Cetus Corporation, Emeryville, CA, United States (U.S. corporation)  
PI US 4705886 19871110  
AI US 1986-888252 19860721 (6)  
RLI Division of Ser. No. US 1985-791332, filed on 25 Oct 1985, now patented,  
Pat. No. US 4617261 which is a continuation-in-part of Ser. No. US  
1984-683263, filed on 18 Dec 1984, now patented, Pat. No. US 4582789  
which is a continuation-in-part of Ser. No. US 1984-591811, filed on 21  
Mar 1984, now abandoned  
DT Utility  
EXNAM Primary Examiner: Schwartz, Richard A.  
LREP Hasak, Janet E.; Halluin, Albert P.  
CLMN Number of Claims: 1  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)  
LN.CNT 2137

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nucleic acids may be labeled by intercalating the alkylating  
intercalation moiety of a labeling reagent into a partially  
double-stranded nucleic acid to form a complex and activating the

complex to cause covalent bonding between the reagent and the nucleic acid. Preferably, the labeled nucleic acid is a hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive. The labeling reagent is of the formula:

[A--[B--L

where A is an alkylating intercalation moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the intercalation and label moieties.

Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5', 8-trimethylpsoralen moiety and L is biotin.

This patent application is a divisional application of copending U.S. Ser. No. 791,332 filed Oct. 25, 1985, now U.S. Pat. No. 4,617,261, which is a continuation-in-part application (CIP) of copending U.S. Ser. No. 683,263 filed Dec. 18, 1984, now U.S. Pat. No. 4,582,789 which is a CIP of copending U.S. Ser. No. 591,811 filed Mar. 21, 1984, now abandoned. This patent application is also related to copending U.S. application Ser. No. 791,323 filed Oct. 25, 1985.

L5 ANSWER 96 OF 98 USPATFULL  
AN 86:57896 USPATFULL  
TI Process for labeling nucleic acids and hybridization probes  
IN Sheldon, III, Edward L., Oakland, CA, United States  
Levenson, Corey H., Oakland, CA, United States  
Mullis, Kary B., Kensington, CA, United States  
Rapoport, Henry, Berkeley, CA, United States  
Watson, Robert M., Berkeley, CA, United States  
PA Cetus Corporation, Emeryville, CA, United States (U.S. corporation)  
PI US 4617261 19861014  
AI US 1985-791332 19851025 (6)  
RLI Continuation-in-part of Ser. No. US 1984-683263, filed on 18 Dec 1984  
which is a continuation-in-part of Ser. No. US 1984-591811, filed on 21  
Mar 1984  
DT Utility  
EXNAM Primary Examiner: Nucker, Christine M.  
LREP Halluin, Albert P.; Hasak, Janet E.  
CLMN Number of Claims: 33  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)  
LN.CNT 2330  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Nucleic acids may be labeled by intercalating the alkylating  
intercalation moiety of a labeling reagent into a partially  
double-stranded nucleic acid to form a complex and activating the  
complex to cause covalent bonding between the reagent and the nucleic  
acid. Preferably, the labeled nucleic acid is a hybridization probe for  
detecting nucleic acid sequences capable of hybridizing with a  
hybridizing region of the nucleic acid. Also preferably the label moiety  
is non-radioactive. The labeling reagent is of the formula:

[A--[B--L

where A is an alkylating intercalation moiety, B is a divalent organic moiety of the formula: ##STR1## where Y is O, NH or N--CHO, x is a number from 1 to 4, y is a number from 2 to 4, and L is a monovalent label moiety, wherein B is exclusive of any portion of the intercalation and label moieties.



Preferably A is a 4-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted-4,5',8-trimethylpsoralen moiety and L is biotin.

L5 ANSWER 97 OF 98 USPATFULL  
AN 86:21811 USPATFULL  
TI Process for labeling nucleic acids using psoralen derivatives  
IN Sheldon, III, Edward L., Oakland, CA, United States  
Levenson, Corey H., Oakland, CA, United States  
Mullis, Kary B., Oakland, CA, United States  
Rapoport, Henry, Berkeley, CA, United States  
PA Cetus Corporation, Emeryville, CA, United States (U.S. corporation)  
PI US 4582789 19860415  
AI US 1984-683263 19841218 (6)  
RLI Continuation-in-part of Ser. No. US 1984-591811, filed on 21 Mar 1984, now abandoned  
DT Utility  
EXNAM Primary Examiner: Nucker, Christine M.  
LREP Halluin, Albert P.; Hasak, Janet E.  
CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)  
LN.CNT 1923  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A labeling reagent of the formula:

[A][B]L

is prepared where A is an alkylating intercalation moiety, B is a divalent organic spacer arm moiety with a straight chain of at least two carbon atoms, and L is a monovalent label moiety capable of producing a detectable signal, e.g., a signal detectable by spectroscopic, photochemical, chemical, immunochemical or biochemical means. Preferably A is a 4'-methylene-substituted psoralen moiety, and most preferably A is a 4'-methylene-substituted 4,5',8-trimethylpsoralen moiety.

This reagent may be used to label nucleic acids, preferably DNA, by intercalating the alkylating intercalation moiety of the reagent into an at least partially double-stranded nucleic acid to form a complex and activating the complex to cause covalent bonding between the reagent and the nucleic acid. Preferably, the labeled nucleic acid is a hybridization probe for detecting nucleic acid sequences capable of hybridizing with a hybridizing region of the nucleic acid. Also preferably the label moiety is non-radioactive.

This reagent may also be used in chromosome banding to label specific regions of chromosomes and thereby differentiate them.

L5 ANSWER 98 OF 98 USPATFULL  
AN 78:56108 USPATFULL  
TI Antigen for trachoma lymphogranuloma venereum (LGV) and non-gonococcal urethritis (NGU)  
IN Caldwell, Harlan D., Seattle, WA, United States  
Kuo, Cho-Chou, Seattle, WA, United States  
Kenny, George E., Seattle, WA, United States  
PA Research Corporation, New York, NY, United States (U.S. corporation)  
PI US 4118469 19781003  
AI US 1976-680927 19760427 (5)  
DT Utility  
EXNAM Primary Examiner: Padgett, Benjamin R.; Assistant Examiner: Nucker, Christine M.  
LREP Cooper, Dunham, Clark, Griffin & Moran  
CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1037

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Solubilized antigens of *C. trachomatis* strain LGV-434 upon analysis using two-dimensional immunoelectrophoresis yielded a single antigen which was found to be consistently precipitated by sera of patients with *C. trachomatis* infections. This antigen as antigen-antibody complex was employed as an immunogen to prepare a rabbit monospecific antiserum to this component or antigen. This monospecific antiserum demonstrated the presence of the antigen in each of the 15 strains of *C. trachomatis* organisms and was non-reactive with strains of *C. psittaci*. The *C. trachomatis* specific antigen was purified by immunoadsorption chromatography using monospecific antiserum as a specific ligand covalently bound to agarose gel columns and the resulting purified antigen employed to detect antibody from the sera of lymphogranuloma venereum patients using counterimmunoelectrophoresis. When the *C. trachomatis* specific antigen is isotopically labeled and utilized in the highly sensitive radioimmune assay antibody to the antigen should be demonstrated and a serological test based thereon should be applicable for the serological diagnosis of non-gonococcal urethritis (NGU).

=>

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

```
NEWS EXPRESS  May 23 CURRENT WINDOWS VERSION IS V6.0a,
               CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
               AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001
NEWS HOURS    STN Operating Hours Plus Help Desk Availability
NEWS INTER    General Internet Information
NEWS LOGIN    Welcome Banner and News Items
NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
NEWS WWW      CAS World Wide Web Site (general information)
```

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:10:44 ON 25 MAY 2001

FILE 'CABA' ENTERED AT 11:11:44 ON 25 MAY 2001  
COPYRIGHT (C) 2001 CAB INTERNATIONAL (CABI)

FILE 'LIFESCI' ENTERED AT 11:11:44 ON 25 MAY 2001  
COPYRIGHT (C) 2001 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 11:11:44 ON 25 MAY 2001  
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAP10' ENTERED AT 11:11:44 ON 25 MAY 2001

COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

=> s Chlamydia

L1 59198 CHLAMYDIA

=> s l1 and composition?

L2 1447 L1 AND COMPOSITION?

=> s l2 and treatment?

L3 925 L2 AND TREATMENT?

=> s l3 and Chlamydia trachomatis

L4 339 L3 AND CHLAMYDIA TRACHOMATIS

=> s l4 and vaccine?

L5 98 L4 AND VACCINE?

=> d l5 bib ab 1-98